Method of molecular diagnosis of chronic myelogenous leukemia

ABSTRACT

A method for detecting chronic myeloid leukemia is provided. The method comprises the step of measuring expression level of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene in a test tissue or a test cell; or determining expression profile of a gene group containing at least one of said genes so as to thereby detect chronic myeloid leukemia.

TECHNICAL FIELD

[0001] This invention relates to a method for detecting chronic myeloid leukemia; a method for evaluating a compound for its effectiveness in treating or preventing chronic myeloid leukemia; a therapeutic or prophylactic agent for chronic myeloid leukemia containing the compound obtained by the evaluation method; a therapeutic or prophylactic agent for chronic myeloid leukemia containing such compound; and a method for determining the risk of suffering from chronic myeloid leukemia.

BACKGROUND ART

[0002] Chronic myeloid leukemia (CML) is a malignant disease caused by abnormal clonal growth of pluripotent hematopoietic stem cells [Kantarjian, H. M. et al.: Blood 82: 691(1993)]. Onset of this disease is believed to be caused by BCR-ABL fusion protein which is produced as a result of reciprocal translocation between chromosomes 9 and 22, and this BCR-ABL fusion protein is believed to act as an active tyrosine kinase to induce uncontrolled cell growth [Era, T. et al.: Proc. Natl. Acad. Sci. USA 97: 1737(2000)]. This uncontrolled cell growth results not only in the increase of undifferentiated blood cells but also in the differentiated blood cells from malignant clone, and as a consequence, the peripheral blood exhibits leukocytosis, thrombocytosis, and like.

[0003] The phase when the malignant clone has not yet lost its differentiation ability is called chronic phase (chronic phase: CP), and in this phase, the patients suffer from relatively mild clinical conditions. In most patients in their chronic phase, blood cell count of the peripheral blood can be controlled by administering interferon (IFN) α or hydroxyurea (HU) [Silver, R. T. et al.: Blood 94: 1517(1999)]. However, malignant blasts of many chronic myeloid leukemia patients lose their differentiation potency after several years, and as a result, the patients exhibits “acute leukemia” like conditions in which only the undifferentiated CML blasts propagate with the decrease in the mature blood cells. This phase is called blast crisis (blast crisis: BC) phase, and some patients are observed to experience accelerated phase (accelerated phase: AP) in the transition from the chronic phase to the blast crisis phase.

[0004] Once the patient is in the blast crisis phase, 50% survival period of the patient is generally as short as about 3 months, and the prognosis is extremely severe. Compared to the cells generally found in acute myeloid leukemia, CML blasts of the patient in the blast crisis phase are resistant to chemotherapy, and the prognosis is difficult to improve even by bone marrow transplantation. In order to improve the prognosis of the patients, it is therefore quite important to clarify the mechanism of the transition from the chronic phase to the accelerated phase or the blast crisis phase at the molecular level to thereby stop such transition. In contrast to the onset of the chronic myeloid leukemia defined by the production of the BCR-ABL fused gene product, the molecular mechanism that results in the advance into the accelerated phase or the blast crisis phase is little clarified. While activation of RAS oncogene product associated with point mutation [LeMaistre, A. et al.: Blood 73: 889(1989); Cogswell, P. C. et al.: Blood 74: 2629(1989)], and inactivation of p53 tumor suppressor gene product [Guran, S. et al.: Haematologia 29: 181(1998); Peller, S. et al.: Gene Chromosome Canc. 21: 2(1998)] have been reported to be associated with the advance of the disease phase, frequency of such events in the patient's specimen is not very high, and these events are unlikely to be the general mechanisms that are responsible for the advance of the chronic myeloid leukemia phase. While abnormality of chromosome 17 where p53 gene is located is often found in the late stage of chronic myeloid leukemia, Fioretos et al. describes that abnormality in the amino acid sequence of the p53 protein is rather rare in these cases, and Fioretos et al. postulates the presence of an unidentified tumor suppressor gene on the same chromosome whose gene abnormality plays an important role in the advance of the chronic myeloid leukemia phase [Fioretos, T. et al.: Blood 94: 225(1999)].

[0005] DNA microarray (also referred to as a DNA chip) is a recently developed system for analyzing gene expression, and this system has enabled macroscopic observation of gene expression of several thousands to tens of thousands of genes by repeating the experiment for several times. However, no report is so far known that has analyzed gene expression profile of the chronic myeloid leukemia patients by such system.

DISCLOSURE OF THE INVENTION

[0006] An object of this invention is to provide a method for detecting chronic myeloid leukemia; a method for detecting risk factor for chronic myeloid leukemia; a method for evaluating a compound for its effectiveness in treating or preventing chronic myeloid leukemia; a compound having therapeutic or prophylactic effects obtained by such evaluation method; and a therapeutic or prophylactic agent for chronic myeloid leukemia containing such compound as its effective component.

[0007] The inventors of the present invention have made an extensive investigation to solve the problems as described above, and succeeded in identifying the genes whose expression level alters in phase-specific manner in the AC133 protein-positive hematopoietic stem cell of the patients suffering from chronic myeloid leukemia. The present invention has been completed on the bases of such identification.

[0008] This invention provides a method for detecting chronic myeloid leukemia comprising the step of measuring expression level of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene in a test tissue or a test cell; or determining expression profile of a gene group containing at least one of said genes to thereby detect chronic myeloid leukemia. IFIT-2 gene is the gene for the interferon-induced protein represented by the nucleotide sequence shown in SEQ ID NO: 1 [Levy, Det al.: Proc. Natl. Acad. Sci. USA 83: 8929(1986)], or its allelic variant; LAGE-1 gene is the gene represented by the nucleotide sequence shown in SEQ ID NO: 3 [Lethe, B et al.: Int. J. Cancer 76: 903(1998)] or its allelic variant; BAGE gene is the gene represented by the nucleotide sequence shown in SEQ ID NO: 5 [Boel, P et al.: Immunity 2: 167(1995)] or its allelic variant; DDB1 gene is the gene for a DNA damage-binding protein represented by the nucleotide sequence shown in SEQ ID NO: 7 [Dualan, R et al.: Genomics 29: 62(1995)] or its allelic variant; ETS2 gene is the gene represented by the nucleotide sequence shown in SEQ ID NO: 9 [Watson, D. K. et al.: Proc. Natl. Acad. Sci. USA 85: 7862(1988)] or its allelic variant; PIASy gene is the gene represented by the nucleotide sequence shown in SEQ ID NO: 11 [Liu, B et al.: Proc. Natl. Acad. Sci. USA 95: 10626(1998)] or its allelic variant; PIASx-α gene is the gene represented by the nucleotide sequence shown in SEQ ID NO: 13 [Liu, B et al.: Proc. Natl. Acad. Sci. USA 95: 10626(1998)] or its allelic variant; PIASx-β gene is the gene represented by the nucleotide sequence shown in SEQ ID NO: 15 [Liu, B et al.: Proc. Natl. Acad. Sci. USA 95: 10626(1998)] or its allelic variant; and DAPK3 gene is the gene represented by the nucleotide sequence shown in SEQ ID NO: 17 [Kawai, T. et al.: Mol. Cell. Biol. 18: 1642(1998)] or its allelic variant. The genes as described above are summarized in Table 1, below. TABLE 1 SEQ ID NO: SEQ ID NO: Name of Accession No. (Nucleotide (Amino acid the gene (GenBank) sequence) sequence) IFIT-2 M14660/X07557 SEQ ID NO: 1 SEQ ID NO: 2 LAGE-1 AJ223041 SEQ ID NO: 3 SEQ ID NO: 4 BAGE U19180 SEQ ID NO: 5 SEQ ID NO: 6 DDB1 U18299 SEQ ID NO: 7 SEQ ID NO: 8 ETS-2 J04102 SEQ ID NO: 9 SEQ ID NO: 10 PIASy AF077952 SEQ ID NO: 11 SEQ ID NO: 12 PIASx-α AF077953 SEQ ID NO: 13 SEQ ID NO: 14 PIASx-β AF077954 SEQ ID NO: 15 SEQ ID NO: 16 DAPK3 AB007144/NM001348 SEQ ID NO: 17 SEQ ID NO: 18

[0009] The test cell used may be a bone marrow cell or a blood cell, and in particular, an undifferentiated stem cell which propagates in the patient suffering from chronic myeloid leukemia, namely, a pluripotent hematopoietic stem cell (in particular, AC133 protein-positive hematopoietic stem cell). The measurement of the expression level of the gene or the determination of the expression profile of the gene group may be conducted at the level of either mRNA or protein. The measurement of the expression level of the gene or the determination of the expression profile of the gene group at the mRNA level may be conducted, for example, by gene amplification or by using a DNA microarray. The measurement of the expression level of the gene or the determination of the expression profile of the gene group at the protein level may be conducted, for example, by means of immunological method or by using a protein chip.

[0010] This invention also provides a method for determining phase of the chronic myeloid leukemia wherein the phase of the chronic myeloid leukemia is determined by using the detection method of the chronic myeloid leukemia according to any one of the detection methods as described above. The phase may be selected from chronic phase, accelerated phase, and blastic phase.

[0011] This invention also provides a method for evaluating a compound for its effectiveness in treating or preventing chronic myeloid leukemia, comprising the steps of:

[0012] (a) administering the compound to be evaluated to a test animal or a test cell, or bringing the compound in contact with a test animal or a test cell; and

[0013] (b) confirming whether the compound regulates expression level of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene, or a gene which is functionally equivalent to such gene in test animal or the test cell.

[0014] This invention also provides a method for evaluating a compound for its effectiveness in treating or preventing chronic myeloid leukemia, comprising the steps of:

[0015] (a) bringing the compound to be evaluated in contact with a test animal or a test cell containing a fusion gene of an expression-regulatory region of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene; and a reporter gene; and

[0016] (b) measuring the level of the reporter gene expressed in the test animal or the test cell to evaluate the compound.

[0017] This invention also provides a method for evaluating a compound for its effectiveness in treating or preventing chronic myeloid leukemia, comprising the steps of:

[0018] (a) bringing the compound to be evaluated in contact with a protein encoded by a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene; and

[0019] (b) measuring the activity of the protein to evaluate the compound.

[0020] This invention also provides method for evaluating a compound for its effectiveness in treating or preventing chronic myeloid leukemia, comprising the steps of:

[0021] (a) bringing the compound to be evaluated in contact with a STAT protein whose activity is inhibited by a protein coded by PIASy gene or PIASx-β gene; and

[0022] (b) measuring the activity of the STAT protein to evaluate the compound.

[0023] This invention also provides a therapeutic or prophylactic agent for chronic myeloid leukemia containing the compound obtained by the evaluation method of any one of the evaluation method as described above as its effective component.

[0024] This invention also provides a reagent for research purpose, or an agent for detection, treatment, or prevention of chronic myeloid leukemia comprising an antibody directed against a protein encoded by a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-P gene, and DAPK3 gene, as an active ingredient.

[0025] This invention also provides a method for determining the risk of being susceptible for chronic myeloid leukemia comprising the step of detecting genetic polymorphism which causes abnormality in expression level of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-P gene, and DAPK3.

[0026] This invention also provides a method for determining the risk of being susceptible for chronic myeloid leukemia comprising the step of detecting genetic polymorphism which causes abnormality in biological activity of a protein encoded by a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene.

[0027] This invention also provides a therapeutic or prophylactic agent for chronic myeloid leukemia comprising an antisense nucleic acid which is capable of specifically hybridizing with the mRNA of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, and ETS2 gene.

[0028] This invention also provides a therapeutic or prophylactic agent for chronic myeloid leukemia comprising a ribozyme capable of specifically cleaving the mRNA of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, and ETS2 gene.

[0029] Next, the present invention is described in further detail.

[0030] This invention relates to a unique method for detecting chronic myeloid leukemia which is quite different from conventional methods used for detecting chronic myeloid leukemia, wherein expression level of a particular gene or expression profile of a particular gene group in the test tissue or the test cell is used as an index for the detection of the chronic myeloid leukemia. The term “expression level”, as used herein, refers to an absolute or relative amount of the transcription product of the particular gene (hereinafter also referred to as the “mRNA level”) or an absolute, or relative amount of the translation product of the particular gene (hereinafter also referred to as the “protein level”). The term “expression profile”, as used herein, refers to a patternized profile of expression levels of a plurality of genes including the above-mentioned particular gene.

[0031] 1. Detection Method of Chronic Myeloid Leukemia According to the Present Invention

[0032] The present invention has revealed that IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene exhibit unique alteration of expression level in the AC133-positive hematopoietic stem cell of patients suffering from chronic myeloid leukemia. Accordingly, these genes are useful as a marker gene for chronic myeloid leukemia, and chronic myeloid leukemia can be detected by measuring the expression level of such gene or by determining the expression profile of the gene group including such gene in the tissue from the donor (used interchangeably herein with “test tissue”) or the cell from the donor (used interchangeably herein with “test cell”). The test cell used may be a bone marrow cells or a blood cell, and preferably a pluripotent hematopoietic stem cell, and most preferably an AC133-positive hematopoietic stem cell, an Flt3/Flk2 (GenBank XM007174)-positive hematopoietic stem cell, or a KDR/Flk (GenBank NM002253)-positive hematopoietic stem cell. While the test cell used in the Examples of the present invention is the AC133-positive hematopoietic stem cell from bone marrow, it is to be noted that the AC133-positive hematopoietic stem cell is also found in peripheral blood [Blood 95: 3106-3112 (2000)], and a blood cell can also be used in the detection method of the present invention.

[0033] Specifically, if the expression level of the gene as described above in the test tissue or the test cell is increased or decreased in comparison with the expression level in the chronic myeloid leukemia revealed by the present invention, the donor can be evaluated as suffering from the chronic myeloid leukemia. To be more specific, the genes as described above exhibit alteration of the expression level as described below in each phase of the chronic myeloid leukemia.

[0034] More specifically, the expression level of IFIT-2 gene increases in the patient of chronic phase chronic myeloid leukemia to the level of about 2 to 500 times higher than that of the normal donor while the expression level reduces again in the accelerated phase and the blast crisis phase. In the case of LAGE-1 gene and BAGE gene, the expression level in the normal donor is either zero or at a very low level if expressed, and the expression is found only in the chronic phase and the expression level again reduces in the accelerated phase and the blast crisis phase. Therefore, if the expression level of such gene in the hematopoietic stem cell of a donor is found to have increased to the level equivalent to the level as described above, the donor can be determined to be a patient of chronic myeloid leukemia and the phase of the disease can be evaluated to be the chronic phase.

[0035] In the hematopoietic stem cells of the patient suffering from chronic myeloid leukemia of the accelerated phase or the blast crisis phase, the expression level of DDBL gene can increase to the level of about 20 to 50 times higher than that of the normal donor or the patient of chronic phase chronic myeloid leukemia, and/or the expression level of ETS2 gene can increase to the level of about 2 to 10 times higher than that of the normal donor or the patient of chronic phase chronic myeloid leukemia. Therefore, if the expression level of such gene in the hematopoietic stem cell of a donor is found to have increased to the level equivalent to the level as described above, the donor can be determined to be a patient of chronic myeloid leukemia and the phase of the disease can be evaluated to be the accelerated phase or the blast crisis phase.

[0036] In the hematopoietic stem cells of the patient suffering from chronic myeloid leukemia of the accelerated phase or the blast crisis phase, the expression level of PIASy gene, PIASx-α and β genes, and DAPK3 gene can uniquely decrease to the level of about ½ to {fraction (1/50)}, respectively, compared to the normal donor or the patient of chronic phase chronic myeloid leukemia. Therefore, if the expression level of such gene in the hematopoietic stem cell of a donor is found to have decreased to the level equivalent to the level as described above, the donor can be determined to be a patient of chronic myeloid leukemia and the phase of the disease can be evaluated to be the accelerated phase or the blast crisis phase.

[0037] The mRNA expression level for the gene can be measured by gene amplification (for example, by PCR or by real time RT-PCR), by using a DNA microarray, or by dot blot hybridization, slot blot hybridization, northern hybridization, or the like. The protein expression level for the gene can be measured by using a protein chip, by an immunological process (for example, by ELISA), or the like.

[0038] In addition, whether the donor suffers from chronic myeloid leukemia can be determined more accurately by specifying expression profile of a gene group including any one of the chronic myeloid leukemia marker genes for the biological sample from the donor, and comparing the resulting expression profile with the expression profile of the case which has been preliminarily identified as the expression profile of the chronic myeloid leukemia. In other words, by this means, even the unchanged expression level shown for a gene can also be monitored and utilized as a control in order to improve the accuracy and reliability of the measurement result. The expression profile is preferably determined by using a DNA microarray in view of convenience, sensitivity, reproducibility, and the like.

[0039] Furthermore, a DNA containing at least a part of the IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-β gene, PIASx-α gene, or DAPK3 gene can be used as a primer or a probe to analyze the gene or the mRNA of the gene. The term “at least a part”, as used herein, means that the oligonucleotide which is used for the primer or the probe comprises a nucleotide sequence containing at least 8 nucleotides corresponding to the DNA sequence of the present invention, and preferably a nucleotide sequence of at least 10 nucleotides, and more preferably a polynucleotide containing at least about 15 to 25 nucleotides having the corresponding sequence.

[0040] 2. Evaluation of the Compound Which May be Effective in Treating or Preventing Chronic Myeloid Leukemia

[0041] A substance, which is capable of normalizing the expression level or the activity level of the chronic myeloid leukemia-marker gene product thereby to enable differentiation of the leukemia cell into a normal cell or suppression of the abnormal growth of the leukemia cell, is expected to be found among some of the compounds which can regulate the expression level of a chronic myeloid leukemia marker gene, the activity of the chronic myeloid leukemia-marker gene product, or the STAT protein activity inhibited by the chronic myeloid leukemia-marker gene. On the bases of such expectation, compounds which may be effective in treating or preventing chronic myeloid leukemia may be determined by the procedure as described below. The term “evaluation”, as used herein, is to a wide concept including both the screening and the validation of a compound.

[0042] (1) Evaluation Using Expression Level of Chronic Myeloid Leukemia Marker Gene for the Index

[0043] A test compound can be evaluated for its effectiveness in the treatment or prevention of the chronic myeloid leukemia by administering the test compound to or by bringing the test compound in contact with a test animal (for example, mouse, rat, or rabbit) or a test cell (for example, a human cell line of chronic myeloid leukemia, human blood cell, or AC 133-positive hematopoietic stem cell), and confirming whether the test compound regulates the expression level of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, DAPK3 gene, or a gene which is functionally equivalent to these genes (i.e. whether the test compound brings the expression level of such a gene to the normal level) in the test animal or the test cell. The test animal or the test cell used may also be an animal or a cell having artificially introduced therein a fusion gene of the region regulating the expression of the IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, or DAPK3 gene with a reporter gene. The reporter gene used is not limited to any specific gene, and exemplary reporter genes include β-galactosidase gene, luciferase gene, green fluorescence protein gene, and the like.

[0044] (2) Evaluation Using Activity-Regulating Ability of the Chronic Myeloid Leukemia Marker Gene for the Index

[0045] A test compound can be evaluated for its effectiveness in the treatment or prevention of the chronic myeloid leukemia by bringing the test compound in contact with a protein coded by IFIT-2 gene, LAGE-I gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-a gene, PIASx-β gene, or DAPK3 gene, and confirming whether the test compound regulates the activity of the protein.

[0046] (3) Evaluation Using the Ability of Regulating the Activity of STAT Protein for the Index

[0047] A test compound can be evaluated for its effectiveness on the treatment or prevention of the chronic myeloid leukemia by bringing the test compound in contact with a STAT protein whose activity is inhibited by the protein coded by PIASy gene, PIASx-α gene, or PIASx-β gene, and confirming that the test compound regulates the activity of the STAT protein.

[0048] 3. Applications of the Antibody Against the Product of a Chronic Myeloid Leukemia Marker Gene

[0049] An antibody against the product of the chronic myeloid leukemia-marker gene can be produced by the procedure as described below. The term “antibody”, as used herein, refers to the entire molecule of the antibody which binds to the product of a chronic myeloid leukemia-marker gene which is the antigen, as well as its fragment (for example, Fab or F(ab′)₂ fragment). The antibody against the product of the chronic myeloid leukemia-marker gene can be produced by any of the techniques known in the art. For example, a monoclonal antibody can be isolated from the culture supernatant of the hybridoma or from the ascites of the mouse administered with the hybridoma, after preparing the cell fusion of a commercially available mouse myeloma cell with the splenocyte from the mouse immunized against the chronic myeloid leukemia-marker gene product. The monoclonal antibody can also be produced from an in vitro system using phage display method. The product of the chronic myeloid leukemia-marker gene used for the antigen does not necessarily have the entire amino acid structure, and may be a peptide having a partial amino acid structure, its variant, derivative, or fusion peptide with other peptides, and the product of the marker gene may be the one produced by any one of genetic engineering technique, biological process, and chemical synthesis. The antibody can be used as a research-purpose reagent used in identifying or quantitating the product of the chronic myeloid leukemia-marker gene in a human biological sample, or as an effective component in a diagnostic, therapeutic, or prophylactic agent for chronic myeloid leukemia. The antibody used in the present invention can also be used as a fragment such as Fab, F(ab′)₂, or its derivative, or as a chimeric antibody or a humanized antibody, all of which are included within the present invention. The product of the chronic myeloid leukemia-marker gene can be immunologically measured by any of the methods known in the art including fluorescein antibody technique, passive hemagglutination, and enzyme antibody technique.

[0050] 4. Application of the Antisense Nucleic Acids, Which Can Hybridize with the mRNAs of Chronic Myeloid Leukemia Marker Gene, and the Ribozymes Capable of Cleaving Such mRNAs

[0051] Of the chronic myeloid leukemia marker genes revealed in this invention, IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, and ETS2 gene are found to exhibit increased mRNA expression levels in the AC133-positive hematopoietic stem cells derived from chronic myeloid leukemia patients. In particular, the expression levels for the DDB1 gene and the ETS2 gene are found to increase in the transition from the accelerated phase to the blast crisis phase in proportion to the malignancy of the chronic myeloid leukemia. Therefore, an antisense nucleic acid (for example, DNA or RNA) which suppresses expression of these genes by specifically hybridizing with the mRNA of these genes, a gene construct expressing such antisense nucleic acid, a ribozyme which specifically cleaves such mRNA, and a gene construct expressing such ribozyme are candidates for the therapeutic agent of the chronic myeloid leukemia. The antisense nucleic acid, the ribozyme, and the gene constructs expressing such antisense nucleic acid or ribozyme can be produced by a method known in the art by using the nucleotide sequence of the IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, or ETS2 gene.

[0052] 5. Therapeutic or Prophylactic Agent for Chronic Myeloid Leukemia

[0053] Chronic myeloid leukemia marker genes are genes whose expression level markedly alters in the blood cell of the patient suffering from chronic myeloid leukemia. Therefore, a substance capable of regulating the expression level of the chronic myeloid leukemia marker gene so as to get it back to its normal level in the blood cell is useful for treating or preventing the chronic myeloid leukemia. Exemplary substances which regulate the expression level of the chronic myeloid leukemia marker gene in the blood cell back to the normal level include the compound evaluated in the above 2, the antibody obtained in the above 3, and the antisense nucleic acid, the ribozyme, and the gene constructs expressing these obtained in the above 4.

[0054] When such substance is used as a therapeutic or prophylactic agent for chronic myeloid leukemia, the substance can be formulated into an appropriate dosage form by mixing the substance with a carrier generally used in the art depending on the administration route. For example, in the case of oral administration, the substance may be formulated into a tablet, capsule, granule, powder, liquid, or other dosage form, and a solid formulation for oral administration may be prepared by using an excipient, a binder, or a lubricant, or in further combination with a colorant or a disintegrant. Exemplary excipients include lactose, starch, talc, magnesium stearate, crystalline cellulose, methyl cellulose, carboxymethylcellulose, glycerin, sodium alginate, and gum arabic. Exemplary binders include polyvinyl alcohol, polyvinylether, ethyl cellulose, gum arabic, shellac, and saccharose. Exemplary lubricants include magnesium stearate and talc. The colorant, disintegrant, and the like used may be those known in the art. The tablet may be coated by the method well known in the art. The liquid formulation may be an aqueous or oleaginous suspension, a solution, a syrup, a elixir, or the like which is prepared by the method generally used in the art. When an injection is prepared, the substance as described above may be mixed with a pH adjusting agent, a buffer, a stabilizer, an isotonic agent, a local anesthetic, or the like, and a subcutaneous, intramuscular, or intravenous injection may be produced by a conventional method. Exemplary bases used in producing a suppository include cacao butter, polyethylene glycol, and other oil base.

[0055] The dose of the resulting preparation can not be determined universally since the dose differs by the conditions, weight, age, and the like of the patient. However, the compound of the present invention is generally administered at a dose in the range of about 0.1 to 1000 mg, which is administered in 1 to 4 times a day. If desired, the administration may be accomplished at an interval of 1 to several days, or at an even longer interval.

[0056] 6. Determination of Susceptibility for Chronic Myeloid Leukemia by Utilizing Genetic Polymorphism

[0057] Liability to suffer from chronic myeloid leukemia (susceptibility for chronic myeloid leukemia) can be determined by detecting the genetic polymorphism which results in the abnormal expression of the marker gene for chronic myeloid revealed by the present invention, or by the polymorphism which results in the abnormal activity of the product of such gene. Exemplary genetic polymorphisms include minisatellite DNA, microsatellite DNA, and SNP (single nucleotide polymorphism), and such genetic polymorphism may be identified as described below. Namely, genetic polymorphism may be identified by sequencing the region of the chronic myeloid leukemia marker gene revealed by the present invention and the region which may be associated with the increase or decrease of the expression level of such gene in both the group of normal donors and the group of chronic rheumatism patients to thereby determine the polymorphic site, and then calculating the allele frequency of the polymorphic site thus determined and finding the allele whose frequency is significantly higher in the patient group to thereby identify the polymorphism correlated to the chronic myeloid leukemia.

[0058] The genetic polymorphism thus determined is preferably detected, for example, by determining the nucleotide sequence of the polymorphic site of the genomic DNA from the donor; by using a method which utilizes the difference in physicochemical nature of the DNA sample or the difference of the restriction site which depends on the changed nucleotide sequence for the polymorphic site (for example, by the method utilizing the difference in the mobility of the DNA sample including the polymorphic site in gel electrophoresis, capillary electrophoresis, or other electrophoretic means); by using a detection probe which is appropriate for detecting the particular polymorphic site; or by a method using mass spectroscopy. The method used is not limited to those described above as long as the method is capable of detecting the genetic polymorphism as described above, and any method known in the art can be employed for the detection. In any of the detection method as described above, it is to be noted that the DNA sample to be assayed is a sample of human origin, and the type of the sample is not limited as long as the sample contains the DNA to be assayed. Exemplary samples are body fluids such as blood, bone marrow, semen, ascites, and urine; cells from the tissue such as liver; hairs such as those on the head. Genomic DNA can be extracted, purified, and prepared from these samples by the method generally used in the art.

[0059] In the method for detecting chronic myeloid leukemia risk factor according to the present invention, the donor is determined to have a high risk of suffering from chronic myeloid leukemia when the polymorphism detected for the donor is the one whose frequency is significantly high in a chronic myeloid leukemia patient, and the donor is determined to have a low risk of suffering from chronic myeloid leukemia when the polymorphism detected is not such type.

BRIEF DESCRIPTION OF DRAWINGS

[0060]FIG. 1 is a schematic view showing pMX-tetOFF/PIASy-F constructed in Example 5.

[0061]FIG. 2A is a profile view showing cell number of KCL22 cell carrying pMX-tetOFF/PIASy-F or pMX-tetOFF introduced therein in relation to day of growth, and FIG. 2B is a profile view showing survival rate of KCL22 cell carrying pMX-tetOFF/PIASy-F or pMX-tetOFF introduced therein in relation to day of growth.

[0062]FIG. 3 is a micrograph of KCL22 cell carrying pMX-tetOFF/PIASy-F or pMX-tetOFF introduced therein.

BEST MODE FOR CARRYING OUT THE INVENTION

[0063] Next, the present invention is described in further detail by referring to Examples of the invention which by no means limit the scope of the present invention.

EXAMPLE 1 Preparation of AC133 Positive Cell

[0064] AC133-positive hematopoietic stem cells were prepared from donors by the procedure as described below. First, bone marrow aspirates were obtained from 14 donors (normal donors: 2, chronic phase patient: 7, accelerated phase patient: 2, and blast crisis phase patient: 3) after obtaining informed consent. Next, bone marrow mononuclear cells (MNC) were isolated and purified from the thus obtained bone marrow aspirates by Ficoll-Hypaque density gradient centrifugation, and the cells were washed with PBS. The bone marrow mononuclear cells were then suspended in 300 μl MACS buffer [PBS/3% fetal calf serum (FCS)/2 mM EDTA], and AC133 positive cell in the bone marrow mononuclear cells were labeled with anti-AC133 MicroBeads by adding 100 μl each of FcR blocking reagent and solution of anti-AC133 antibody conjugated to magnetic beads included in the ACC133-positive cell isolation kit (Militenyi Biotec, Auburn, Calif.), and allowing the reaction to take place at 4° C. for 30 minutes to thereby label the AC133 positive cell in the bone marrow mononuclear cell with the anti-AC133 MicroBeads. After thoroughly washing the bone marrow mononuclear cells with MACS buffer, miniMACS column (Militenyi Biotec, Auburn, Calif.) was used to obtain the AC133 positive cells. When the resulting AC133 positive cells were evaluated for their purity by staining with Wright-Giemsa solution (Muto Pure Chemicals), juvenile hematopoietic stem cells constituted 80% or more of the total cells in the samples from all donors.

EXAMPLE 2 Preparation of cRNA

[0065] AC133 positive cells from each donor obtained in Example 1 were used to prepare cRNA for gene expression analysis. First, total RNA was purified from each AC133 positive cell by using RNAzol B reagent (TEL-TEST, Friendswood, Tex.). Next, to the resulting total RNA was added T7-dT primer: 5′-tctagtcgacggccagtgaattgtaatacgactcactatagggcgtttttttttttttttttt-3′ (SEQ ID NO: 19) to hybridize the primer to the mRNA in the total RNA, and cDNA chain complementary to the mRNA was synthesized by using reverse transcriptase SuperScript II (Life Technologies, Rockville, Md.). Using SuperScript choice system (Life Technologies, Rockville, Md.), a double-strand cDNA was then synthesized by using the resulting single strand cDNA as a template. cRNA was then synthesized from the resulting double-strand cDNA by using Ampliscribe transcription kit (Epicentre Technologies, Madison, MI). This procedure was repeated twice to finally obtain 5 to 70 μg of cRNA from the AC 133 positive cells of each patient.

EXAMPLE 3 Analysis of Gene Expression Using DNA Microarray

[0066] ExpressChip DNA microarray system (Mergen, San Leandro, Calif.) and the cRNA obtained in Example 2 were used to analyze the gene expression in the AC133 positive cell from each donor. Double-stranded cDNA was synthesized from 1 μg of the cRNA, and biotin-labeled cRNA was obtained from the resulting double-stranded cDNA by using Ampliscribe transcription kit (Epicentre Technologies, Madison, MI) and biotin-CTP (Life Technologies, Rockville, Md.) for the substrate. Next, the labeled cRNA was hybridized with 3 types of DNA microarrays (HO-1, HO-2, and HO-3; Mergen, San Leandro, Calif.) each having 1152 types of oligonucleotides from human gene spotted thereon. This means that expression levels for 3456 types of genes in total were analyzed for each of the AC133 positive cell from each donor. The DNA microarray after the hybridization was brought in contact with streptavidin, and the microarray was reacted with anti-streptavidin primary antibody, and then, with Cy3 conjugated secondary antibody. It is to be noted that the streptavidin, the anti-streptavidin primary antibody, and the Cy3-conjugated secondary antibody were those purchased from Mergen (San Leandro, Calif.), and the experiment was carried out in accordance with the protocol attached to the ExpressChip DNA microarray system (Mergen, San Leandro, Calif.).

[0067] Next, fluorescence intensity of each gene spot was measured with GMS418 array scanner (Affymetrix, Santa Clara, Calif.), and the measurements were converted into a value by using ImaGene 3.0 (BioDiscovery, Los Angeles, Calif.). The resulting data were statistically processed by GeneSpring 3.2 (Silicon Genetics, Redwood, Calif.). To be more specific, signal intensity of all spots were digitized in every hybridization, and the values were normalized for the average spot intensity. The resulting data were subjected to cluster analysis to obtain a genetic tree (also referred to as a dendrogram) wherein genes having similar expression profile are arranged near a single tree. By this procedure, gene clusters which are active only in a particular disease phase or in a subgroup of the disease phase were found. In addition, in order to visualize the phase-specific genes in the chronic myeloid leukemia, average expression intensity of the genes was calculated for the chronic phase, the accelerated phase, and the blast crisis phase, and the genetic tree was again depicted on the bases of such values. The genes exhibiting expression level alteration in a manner specific to the chronic phase, the accelerated phase and the blast crisis phase were picked out from this average tree. The genes selected are summarized in Table 2. The unit of the expressed amount shown in Table 2 is arbitrary, and the values of 0.6 or less means that the expression was below the detection limit. The values are not absolute, and may vary by the conditions of the patient, preparation of the mRNA, and the conditions of the DNA microarray. TABLE 2 Genes which showed alteration in the expression level Amount expressed Accelerated Blast crisis (Arbitrary unit) Normal Chronic phase phase phase IFIT-2 17.8 128.7 7.9 3.8 LAGE-1 <0.6 20.1 <0.6 <0.6 BAGE <0.6 19.0 <0.6 <0.6 DDB1 1.0 4.5 17.3 23.9 ETS-2 1.5 2.0 4.7 7.5 PIASy 26.1 52.4 4.2 10.0 PIASx-α, β 5.8 16.8 1.7 1.5 DAPK3 63.7 109.4 9.2 20.7

[0068] 39 genes were found to exhibit specific expression in the chronic phase. Among such chronic phase-specific genes, the most notable was interferon-induced protein with tetratricopeptide repeats 2 (IFIT-2) gene (SEQ ID NO: 1). Transcription of the IFIT-2 gene was very active in the 5 samples (CP-3 to CP-7) out of the 7 samples taken from chronic phase donors (CP-1 to CP-7), while very weak or no transcription was found in the samples taken from normal donors or chronic myeloid leukemia patients of other disease phase. In samples CP-6 and CP-7, LAGE-1 gene (SEQ-ID NO: 3) and B melanoma antigen (BAGE) gene (SEQ ID NO: 5) were also found to exhibit specific expression.

[0069] By using the same average tree, attempt was made to identify genes whose expression is not found in the AC133 positive cells from a normal donor or a patient of chronic phase while the expression is induced in the AC133 positive cell from the patient of accelerated phase or blast crisis phase. As a result, DNA damage binding protein (DDB1) gene (SEQ ID NO: 7) and ETS2 transcription factor gene (SEQ ID NO: 9) were found. DDB1 is involved in the DNA repair mechanism, and loss of its activity is related to complementation group E of xeroderma pigmentosum. Loss of stability of the DNA and various types of chromosome aberration are often found in the blast from chronic myeloid leukemia patient of advanced phase. Accordingly, the induction of the DDB1 gene expression as seen here is believed to reflect the DNA damage accumulated in the leukemia cell of the patients in the accelated phase or the blast crisis phase. In addition, both DDB1 gene and ETS2 gene are induced in CP-1 patient, indicating the possibility that this patient is in the course of the transfer to the accelerated phase or the blast crisis phase.

[0070] By using the same average tree, attempt was also made to identify genes whose expression is reduced with the phase transfer to the accelerated phase or the blast crisis phase. 21 genes were then found to exhibit high expression in the AC133 positive cells taken from normal donors or patients in their chronic phase while the expression is reduced in the AC133 positive cells taken from patients in their accelerated phase or blast crisis phase. Among such genes, PIASy gene (SEQ ID NO: 11), PIASx-α gene (SEQ ID NO: 13), and PIASx-β gene (SEQ ID NO: 15) exhibited most remarkable reduction. PIAS 1 and PIAS3 bind to STAT1 and STAT3, respectively, and suppress their activity. Accodingly, although little is known for a protein to which PIASy binds, it is postulated that PIASy may have some function to regulate a member of STAT pathway proteins. It is known that STAT protein is frequently phosphorylated in excess and is activated in the cells derived from individuals suffering from various types of leukemia. Activation of the STAT protein occurs upon introduction of the BCR-ABL kinase into the hematopoietic system, and this indicates the possibility of the STAT protein being a mediator of the BCR-ABL signaling. It was thus speculated that overexpression of PIASy hinders transport of the activated STAT proteins in CML blast cells in chronic phase, while loss of PIASy results in uncontrolled blast cell growth that leads to the progress of the disease phase.

EXAMPLE 4 Confirmation of Expression Level by Real Time PCR

[0071] For the IFIT-2 gene and the PIASy gene which had been identified to be the phase-specific genes in chronic myeloid leukemia in Example 3, real time PCR was carried out to confirm their expression level in the AC133 positive cells from normal donors and patients of each disease phases. First, cDNA was prepared from the AC133 positive cells of patients by the procedure as described in Examples 1 and 2. The resulting cDNA was subjected to PCR using SYBR Green PCR Core Reagents (PE Applied Biosystems, Foster City, Calif.). In the PCR, the primers used for the amplification IFIT-2 gene were 5′-ctgcggtatggcaactttcag-3′ (SEQ ID NO: 20) and 5′-aggaatgccaagacatgcaa-3′ (SEQ ID NO: 21), and the primers used for the amplification of PIASy gene were 5′-aactacggcaagagctactcggtg-3′ (SEQ ID NO: 22) and 5′-gttcatctgcaggtagaagacggc-3′ (SEQ ID NO: 23). β-actin gene was also used for the control according to the method used in the art. ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems) was used to determine the cycle threshold (CT value) at which the exponential growth of the PCR product is first detected in the real time monitoring of the incorporation of the SYBR Green dye to the PCR product. Amount of the target gene in relation to the β-actin mRNA amount was calculated from the CT value of the cDNA corresponding to the β-actin gene and the target gene. The amount of IFIT-2 gene and PIASy gene expressed in the AC133 positive cells from the patients of each disease phase was then found to be consistent with the measurement of Example 3 obtained by using a DNA microarray confirming the reproducibility in the expression of these genes.

EXAMPLE 5 Effects of PIASy Gene Introduction

[0072] PIASy gene which had been identified in Example 3 to be a phase-specific gene for the chronic myeloid leukemia was introduced in a cell from a chronic myeloid leukemia patient of blast crisis phase to thereby examine the effects of the PIASy gene expression.

[0073] The expression vector containing the PIASy gene was constructed as described below. First, pMX-tetOFF vector was prepared by introducing the cDNA coding for tTAER and ires-BSR and tetO fragments in pMX retroviral vector (Onishi et al.: Exp. Hematol., 24,: 324-329 (1996)). Next, PIASy-F gene coding for PIASy (PIASy-F) having FLAG epitope tag (Eastman Kodak) conjugated at the C terminal was amplified by the PCR using PIASy cDNA (Helix Research Institute) for the template. PIASy-F gene was then ligated to the downstream of the tetO fragment in the pMX-tetOFF vector to thereby construct the expression vector (pMX-tetOFF/PIASy-F) (FIG. 1). The resulting expression vector was introduced in a packaging cell line (PA317, American Type Culture Collection).

[0074] In this Example, KCL22 cells (American Type Culture Collection) were used for the cell from a chronic myeloid leukemia patient in the blast crisis phase. KCL22 cells were infected with the pMX-tetOFF/PIASy-F in the culture supernatant of the PA317 by treating the cell in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) for 24 hours in the presence RetroNectin (Takara Shuzo). The KCL22 cells recovered were then cultivated in the RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) further supplemented with 5 μg/ml of blasticidin and 1 μg/ml of tetracycline. PIASy-F gene in the expression vector was then expressed by cultivating the KCL22 cells in the RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) having 2 μM of 17β-estradiol added thereto.

[0075] It is to be noted that the expression vector (pMX-tetOFF/PIASy-F) shown in FIG. 1 does not express the gene (PIASy-F gene) in the downstream of tetO when tetracycline is present and β estradiol is absent. In contrast, the expression vector (pMX-tetOFF/PIASy-F) expresses the gene (PIASy-F gene) in the downstream of tetO when tetracycline is absent and β estradiol is present. The effects of the PIASy gene expression was confirmed by examining the growth of KCL22 cells carrying pMX-tetOFF/PIASy-F introduced therein.

[0076] To be more specific, the KCL22 cells carrying pMX-tetOFF introduced therein and the KCL22 cells carrying pMX-tetOFF/PIASy-F introduced therein were evaluated for their cell number and the survival rate both under the conditions that allow expression of the gene in the downstream of tetO and under the conditions that do not allow expression of the gene in the downstream of tetO. It is to be noted that KCL22 cells cultivated in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) in both conditions.

[0077] The results of evaluating the cell number and the survival rate are shown in FIGS. 2A and 2B, respectively. As shown in FIGS. 2A and 2B, both the cell number and the survival rate decreased in proportion to the growing period of the KCL22 cells expressing PIASy gene. On the contrary, the cell number and the survival rate for the KCL22 cells carrying pMX-tetOFF/PIASy-F, which show no expression of the PIASy gene (“PIASy (−)” in FIG. 2), were not different from those for the KCL22 cells carrying pMX-tetOFF irrespective of the growing period of the cells.

[0078]FIGS. 3A and 3B are photomicrographs (×400) of the KCL22 cells carrying pMX-tetOFF introduced therein and the KCL22 cells carrying pMX-tetOFF/PIASy-F introduced therein when these cells were cultivated for 6 days under the conditions that allow expression of the gene in the downstream of tetO. FIG. 3A is the photomicrograph of the KCL22 cells carrying pMX-tetOFF introduced therein (MOCK), and FIG. 3B is the photomicrograph of the KCL22 cells carrying pMX-tetOFF/PIASy-F introduced therein (PIASy). It is to be noted that both KCL22 cells were stained with Wright-Giemsa solution. As shown in FIGS. 3A and 3B, the KCL22 cells carrying pMX-tetOFF introduced therein showed normal phenotype (intermediate sized cell having a basoplilic cytoplasm, high proportion of nucleus in relation to cytoplasm, and good nuclear structure) while the KCL22 cells carrying pMX-tetOFF/PIASy-F introduced therein (PIASy) showed apoptotic change (size reduction of the cell, and contraction and fragmentation of the nucleus).

[0079]FIGS. 2 and 3 revealed that expression of the PIASy-F gene in the KCL22 cells carrying pMX-tetOFF/PIASy-F introduced therein results in the induction of apoptosis in the KCL22 cells. PIASy protein has been recently demonstrated to inhibit activity of STAT1, and it is postulated that the apoptosis as described above is induced by the inhibition of the STAT1 in the KCL22 cells. High-level expression of the PIASy gene has been observed in the AC133 positive cells derived from each of normal donors and chronic patients, and it may relate to the reduced risk of chronic patients to progress into the blast crisis phase.

INDUSTRIAL APPLICABILITY

[0080] Provided by this invention are a method for detecting chronic myeloid leukemia; a method for evaluating a compound for its effectiveness in treating or preventing chronic myeloid leukemia; a compound which is effective in treating or preventing chronic myeloid leukemia containing the compound obtained by such evaluation method; a therapeutic or prophylactic agent for chronic myeloid leukemia containing such compound; and a method for determining the risk of being susceptible for chronic myeloid leukemia.

1 23 1 2581 DNA Homo sapiens CDS (76)..(1494) 1 agaagaggaa gatttctgaa gagtgcagct gcctgaaccg agccctgccg aacagctgag 60 aattgcagtg caacc atg agt gag aac aat aag aat tcc ttg gag agc agc 111 Met Ser Glu Asn Asn Lys Asn Ser Leu Glu Ser Ser 1 5 10 cta cgg caa cta aaa tgc cat ttc acc tgg aac ttg atg gag gga gaa 159 Leu Arg Gln Leu Lys Cys His Phe Thr Trp Asn Leu Met Glu Gly Glu 15 20 25 aac tcc ttg gat gat ttt gaa gac aaa gta ttt tac cgg act gag ttt 207 Asn Ser Leu Asp Asp Phe Glu Asp Lys Val Phe Tyr Arg Thr Glu Phe 30 35 40 cag aat cgt gaa ttc aaa gcc aca atg tgc aac cta ctg gcc tat cta 255 Gln Asn Arg Glu Phe Lys Ala Thr Met Cys Asn Leu Leu Ala Tyr Leu 45 50 55 60 aag cac ctc aaa ggg caa aac gag gca gcc ctg gaa tgc tta cgt aaa 303 Lys His Leu Lys Gly Gln Asn Glu Ala Ala Leu Glu Cys Leu Arg Lys 65 70 75 gct gaa gag tta atc cag caa gag cat gct gac cag gca gaa atc aga 351 Ala Glu Glu Leu Ile Gln Gln Glu His Ala Asp Gln Ala Glu Ile Arg 80 85 90 agt ctg gtc acc tgg gga aac tat gcc tgg gtc tac tat cac atg ggc 399 Ser Leu Val Thr Trp Gly Asn Tyr Ala Trp Val Tyr Tyr His Met Gly 95 100 105 cga ctc tca gac gtt cag att tat gta gac aag gtg aaa cat gtc tgt 447 Arg Leu Ser Asp Val Gln Ile Tyr Val Asp Lys Val Lys His Val Cys 110 115 120 gag aag ttt tcc agt ccc tat aga att gag agt cca gag ctt gac tgt 495 Glu Lys Phe Ser Ser Pro Tyr Arg Ile Glu Ser Pro Glu Leu Asp Cys 125 130 135 140 gag gaa ggg tgg aca cgg tta aag tgt gga gga aac caa aat gaa aga 543 Glu Glu Gly Trp Thr Arg Leu Lys Cys Gly Gly Asn Gln Asn Glu Arg 145 150 155 gcg aag gtg tgc ttt gag aag gct ctg gaa aag aag cca aag aac cca 591 Ala Lys Val Cys Phe Glu Lys Ala Leu Glu Lys Lys Pro Lys Asn Pro 160 165 170 gaa ttc acc tct gga ctg gca ata gca agc tac cgt ctg gac aac tgg 639 Glu Phe Thr Ser Gly Leu Ala Ile Ala Ser Tyr Arg Leu Asp Asn Trp 175 180 185 cca cca tct cag aac gcc att gac cct ctg agg caa gcc att cgg ctg 687 Pro Pro Ser Gln Asn Ala Ile Asp Pro Leu Arg Gln Ala Ile Arg Leu 190 195 200 aat cct gac aac cag tac ctt aaa gtc ctc ctg gct ctg aag ctt cat 735 Asn Pro Asp Asn Gln Tyr Leu Lys Val Leu Leu Ala Leu Lys Leu His 205 210 215 220 aag atg cgt gaa gaa ggt gaa gag gaa ggt gaa gga gag aag tta gtt 783 Lys Met Arg Glu Glu Gly Glu Glu Glu Gly Glu Gly Glu Lys Leu Val 225 230 235 gaa gaa gcc ttg gag aaa gcc cca ggt gta aca gat gtt ctt cgc agt 831 Glu Glu Ala Leu Glu Lys Ala Pro Gly Val Thr Asp Val Leu Arg Ser 240 245 250 gca gcc aag ttt tat cga aga aaa gat gag cca gac aaa gcg att gaa 879 Ala Ala Lys Phe Tyr Arg Arg Lys Asp Glu Pro Asp Lys Ala Ile Glu 255 260 265 ctg ctt aaa aag gct tta gaa tac ata cca aac aat gcc tac ctg cat 927 Leu Leu Lys Lys Ala Leu Glu Tyr Ile Pro Asn Asn Ala Tyr Leu His 270 275 280 tgc caa att ggg tgc tgc tat agg gca aaa gtc ttc caa gta atg aat 975 Cys Gln Ile Gly Cys Cys Tyr Arg Ala Lys Val Phe Gln Val Met Asn 285 290 295 300 cta aga gag aat gga atg tat ggg aaa aga aag tta ctg gaa cta ata 1023 Leu Arg Glu Asn Gly Met Tyr Gly Lys Arg Lys Leu Leu Glu Leu Ile 305 310 315 gga cac gct gtg gct cat ctg aag aaa gct gat gag gcc aat gat aat 1071 Gly His Ala Val Ala His Leu Lys Lys Ala Asp Glu Ala Asn Asp Asn 320 325 330 ctc ttc cgt gtc tgt tcc att ctt gcc agc ctc cat gct cta gca gat 1119 Leu Phe Arg Val Cys Ser Ile Leu Ala Ser Leu His Ala Leu Ala Asp 335 340 345 cag tat gaa gac gca gag tat tac ttc caa aag gaa ttc agt aaa gag 1167 Gln Tyr Glu Asp Ala Glu Tyr Tyr Phe Gln Lys Glu Phe Ser Lys Glu 350 355 360 ctt act cct gta gcg aaa caa ctg ctc cat ctg cgg tat ggc aac ttt 1215 Leu Thr Pro Val Ala Lys Gln Leu Leu His Leu Arg Tyr Gly Asn Phe 365 370 375 380 cag ctg tac caa atg aag tgt gaa gac aag gcc atc cac cac ttt ata 1263 Gln Leu Tyr Gln Met Lys Cys Glu Asp Lys Ala Ile His His Phe Ile 385 390 395 gag ggt gta aaa ata aac cag aaa tca agg gag aaa gaa aag atg aaa 1311 Glu Gly Val Lys Ile Asn Gln Lys Ser Arg Glu Lys Glu Lys Met Lys 400 405 410 gac aaa ctg caa aaa att gcc aaa atg cga ctt tct aaa aat gga gca 1359 Asp Lys Leu Gln Lys Ile Ala Lys Met Arg Leu Ser Lys Asn Gly Ala 415 420 425 gat tct gag gct ttg cat gtc ttg gca ttc ctt cag gag ctg aat gaa 1407 Asp Ser Glu Ala Leu His Val Leu Ala Phe Leu Gln Glu Leu Asn Glu 430 435 440 aaa atg caa caa gca gat gaa gac tct gag agg ggt ttg gag tct gga 1455 Lys Met Gln Gln Ala Asp Glu Asp Ser Glu Arg Gly Leu Glu Ser Gly 445 450 455 460 agc ctc atc cct tca gca tca agc tgg aat ggg gaa tga agaatagaga 1504 Ser Leu Ile Pro Ser Ala Ser Ser Trp Asn Gly Glu 465 470 tgtggtgccc actaggctac tgctgaaagg gagctgaaat tcctccacca agttggtatt 1564 caaaatatgt aatgactggt atggcaaaag attggactaa gacactggcc ataccactgg 1624 acagggttat gttaacacct gaattgctgg gtcttgagag agcccaagga gttctgggag 1684 agggaccaga ttggggggta ggtccacggg cttggtgata gaattatttc tcgattgact 1744 tcttgagtgc caatttgaac tgtaaccatt tgcttagtca cctttagtgg agtaatccta 1804 ctgggcttgt ttctatattt atataaagca gccaaatcct tcatgtaata ttgaagtcca 1864 tttttgcaat gttgttccat acttggagtc attttgcagc ccatagaggt tagtcctgca 1924 tagccagtaa tgtgctaagt tcatccaaaa gctggcggac caaagtctaa atagggctca 1984 gtatccccct atcgcttatc tctgcctcct tcctcctcct tcccagtcta tcatcaacct 2044 tgagtattct acacatgtga attcaagtgc ctgattaatt gaggtggcaa catagtttga 2104 gacgagggca gagaacagga agatacatag ctagaagcga cgggtacaaa aagcaatgtg 2164 tacaagaaga ctttcagcaa gtatacagag agttcaccct cctcatagtc ataatgtagc 2224 aagtaaagaa tgagaattgg gttcttctac aatacaacta gaaaccaaca attaatggta 2284 tttctttaaa acctgtgtga aaaaataaat gttgtccacc agtagggata ggggaaaagt 2344 aaccaaaaga gagaaagaga aaggaatgct ggtttatctt tgtagattgt aatcgaatgg 2404 agaaatttgc agtattttag ccactattag gaattttttt tttttgtaaa atgaagactg 2464 aactctgttc aaatgctttc atgaacctgg tttgagacgg taggaaagca acaaaacgtg 2524 ggaacctggt gactaagggc ctggtgcaag gacttgggaa atgtcattga taataaa 2581 2 472 PRT Homo sapiens 2 Met Ser Glu Asn Asn Lys Asn Ser Leu Glu Ser Ser Leu Arg Gln Leu 1 5 10 15 Lys Cys His Phe Thr Trp Asn Leu Met Glu Gly Glu Asn Ser Leu Asp 20 25 30 Asp Phe Glu Asp Lys Val Phe Tyr Arg Thr Glu Phe Gln Asn Arg Glu 35 40 45 Phe Lys Ala Thr Met Cys Asn Leu Leu Ala Tyr Leu Lys His Leu Lys 50 55 60 Gly Gln Asn Glu Ala Ala Leu Glu Cys Leu Arg Lys Ala Glu Glu Leu 65 70 75 80 Ile Gln Gln Glu His Ala Asp Gln Ala Glu Ile Arg Ser Leu Val Thr 85 90 95 Trp Gly Asn Tyr Ala Trp Val Tyr Tyr His Met Gly Arg Leu Ser Asp 100 105 110 Val Gln Ile Tyr Val Asp Lys Val Lys His Val Cys Glu Lys Phe Ser 115 120 125 Ser Pro Tyr Arg Ile Glu Ser Pro Glu Leu Asp Cys Glu Glu Gly Trp 130 135 140 Thr Arg Leu Lys Cys Gly Gly Asn Gln Asn Glu Arg Ala Lys Val Cys 145 150 155 160 Phe Glu Lys Ala Leu Glu Lys Lys Pro Lys Asn Pro Glu Phe Thr Ser 165 170 175 Gly Leu Ala Ile Ala Ser Tyr Arg Leu Asp Asn Trp Pro Pro Ser Gln 180 185 190 Asn Ala Ile Asp Pro Leu Arg Gln Ala Ile Arg Leu Asn Pro Asp Asn 195 200 205 Gln Tyr Leu Lys Val Leu Leu Ala Leu Lys Leu His Lys Met Arg Glu 210 215 220 Glu Gly Glu Glu Glu Gly Glu Gly Glu Lys Leu Val Glu Glu Ala Leu 225 230 235 240 Glu Lys Ala Pro Gly Val Thr Asp Val Leu Arg Ser Ala Ala Lys Phe 245 250 255 Tyr Arg Arg Lys Asp Glu Pro Asp Lys Ala Ile Glu Leu Leu Lys Lys 260 265 270 Ala Leu Glu Tyr Ile Pro Asn Asn Ala Tyr Leu His Cys Gln Ile Gly 275 280 285 Cys Cys Tyr Arg Ala Lys Val Phe Gln Val Met Asn Leu Arg Glu Asn 290 295 300 Gly Met Tyr Gly Lys Arg Lys Leu Leu Glu Leu Ile Gly His Ala Val 305 310 315 320 Ala His Leu Lys Lys Ala Asp Glu Ala Asn Asp Asn Leu Phe Arg Val 325 330 335 Cys Ser Ile Leu Ala Ser Leu His Ala Leu Ala Asp Gln Tyr Glu Asp 340 345 350 Ala Glu Tyr Tyr Phe Gln Lys Glu Phe Ser Lys Glu Leu Thr Pro Val 355 360 365 Ala Lys Gln Leu Leu His Leu Arg Tyr Gly Asn Phe Gln Leu Tyr Gln 370 375 380 Met Lys Cys Glu Asp Lys Ala Ile His His Phe Ile Glu Gly Val Lys 385 390 395 400 Ile Asn Gln Lys Ser Arg Glu Lys Glu Lys Met Lys Asp Lys Leu Gln 405 410 415 Lys Ile Ala Lys Met Arg Leu Ser Lys Asn Gly Ala Asp Ser Glu Ala 420 425 430 Leu His Val Leu Ala Phe Leu Gln Glu Leu Asn Glu Lys Met Gln Gln 435 440 445 Ala Asp Glu Asp Ser Glu Arg Gly Leu Glu Ser Gly Ser Leu Ile Pro 450 455 460 Ser Ala Ser Ser Trp Asn Gly Glu 465 470 3 755 DNA Homo sapiens CDS (53)..(595) 3 tcctcgtggg ccctgacctt ctctctgaga gccgggcaga ggctccggag cc atg cag 58 Met Gln 1 gcc gaa ggc cag ggc aca ggg ggt tcg acg ggc gat gct gat ggc cca 106 Ala Glu Gly Gln Gly Thr Gly Gly Ser Thr Gly Asp Ala Asp Gly Pro 5 10 15 gga ggc cct ggc att cct gat ggc cca ggg ggc aat gct ggc ggc cca 154 Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala Gly Gly Pro 20 25 30 gga gag gcg ggt gcc acg ggc ggc aga ggt ccc cgg ggc gca ggg gca 202 Gly Glu Ala Gly Ala Thr Gly Gly Arg Gly Pro Arg Gly Ala Gly Ala 35 40 45 50 gca agg gcc tcg ggg ccg aga gga ggc gcc ccg cgg ggt ccg cat ggc 250 Ala Arg Ala Ser Gly Pro Arg Gly Gly Ala Pro Arg Gly Pro His Gly 55 60 65 ggt gcc gct tct gcg cag gat gga agg tgc ccc tgc ggg gcc agg agg 298 Gly Ala Ala Ser Ala Gln Asp Gly Arg Cys Pro Cys Gly Ala Arg Arg 70 75 80 ccg gac agc cgc ctg ctt cag ttg cac atc acg atg cct ttc tcg tcg 346 Pro Asp Ser Arg Leu Leu Gln Leu His Ile Thr Met Pro Phe Ser Ser 85 90 95 ccc atg gaa gcg gag ctg gtc cgc agg atc ctg tcc cgg gat gcc gca 394 Pro Met Glu Ala Glu Leu Val Arg Arg Ile Leu Ser Arg Asp Ala Ala 100 105 110 cct ctc ccc cga cca ggg gcg gtt ctg aag gac ttc acc gtg tcc ggc 442 Pro Leu Pro Arg Pro Gly Ala Val Leu Lys Asp Phe Thr Val Ser Gly 115 120 125 130 aac cta ctg ttt atc cga ctg act gct gca gac cac cgc caa ctg cag 490 Asn Leu Leu Phe Ile Arg Leu Thr Ala Ala Asp His Arg Gln Leu Gln 135 140 145 ctc tcc atc agc tcc tgt ctc cag cag ctt tcc ctg ttg atg tgg atc 538 Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met Trp Ile 150 155 160 acg cag tgc ttt ctg ccc gtg ttt ttg gct cag gct ccc tca ggg cag 586 Thr Gln Cys Phe Leu Pro Val Phe Leu Ala Gln Ala Pro Ser Gly Gln 165 170 175 agg cgc taa gcccagcctg gcgccccttc ctaggtcatg cctcctcccc 635 Arg Arg 180 tagggaatgg tcccagcacg agtggccagt tcattgtggg ggcctgattg tttgtcgctg 695 gaggaggacg gcttacatgt ttgtttctgt agaaaataaa gctgagctac gaaaaaaaaa 755 4 180 PRT Homo sapiens 4 Met Gln Ala Glu Gly Gln Gly Thr Gly Gly Ser Thr Gly Asp Ala Asp 1 5 10 15 Gly Pro Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala Gly 20 25 30 Gly Pro Gly Glu Ala Gly Ala Thr Gly Gly Arg Gly Pro Arg Gly Ala 35 40 45 Gly Ala Ala Arg Ala Ser Gly Pro Arg Gly Gly Ala Pro Arg Gly Pro 50 55 60 His Gly Gly Ala Ala Ser Ala Gln Asp Gly Arg Cys Pro Cys Gly Ala 65 70 75 80 Arg Arg Pro Asp Ser Arg Leu Leu Gln Leu His Ile Thr Met Pro Phe 85 90 95 Ser Ser Pro Met Glu Ala Glu Leu Val Arg Arg Ile Leu Ser Arg Asp 100 105 110 Ala Ala Pro Leu Pro Arg Pro Gly Ala Val Leu Lys Asp Phe Thr Val 115 120 125 Ser Gly Asn Leu Leu Phe Ile Arg Leu Thr Ala Ala Asp His Arg Gln 130 135 140 Leu Gln Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met 145 150 155 160 Trp Ile Thr Gln Cys Phe Leu Pro Val Phe Leu Ala Gln Ala Pro Ser 165 170 175 Gly Gln Arg Arg 180 5 1004 DNA Homo sapiens CDS (201)..(332) 5 cgccaattta gggtctccgg tatctcccgc tgagctgctc tgttcccggc ttagaggacc 60 aggagaaggg ggagctggag gctggagcct gtaacaccgt ggctcgtctc actctggatg 120 gtggtggcaa cagagatggc agcgcagctg gagtgttagg agggcggcct gagcggtagg 180 agtggggctg gagcagtaag atg gcg gcc aga gcg gtt ttt ctg gca ttg tct 233 Met Ala Ala Arg Ala Val Phe Leu Ala Leu Ser 1 5 10 gcc cag ctg ctc caa gcc agg ctg atg aag gag gag tcc cct gtg gtg 281 Ala Gln Leu Leu Gln Ala Arg Leu Met Lys Glu Glu Ser Pro Val Val 15 20 25 agc tgg agg ttg gag cct gaa gac ggc aca gct ctg tgc ttc atc ttc 329 Ser Trp Arg Leu Glu Pro Glu Asp Gly Thr Ala Leu Cys Phe Ile Phe 30 35 40 tga ggttgtggca gccacggtga tggagacggc agctcaacag gagcaatagg 382 aggagatgga gtttcactgt gtcagccagg atggtctcga tctcctgacc tcgtgatccg 442 cccgccttgg ccttccaaag tgccgagatt acagcgatgt gcattttgta agcactttgg 502 agccactatc aaatgctgtg aagagaaatg tacccagatg tatcattatc cttgtgctgc 562 aggagccggc tcctttcagg atttcagtca catcttcctg ctttgtccag aacacattga 622 ccaagctcct gaaagatgta agtttactac gcatagactt ttaaacttca accaatgtat 682 ttactgaaaa taacaaatgt tgtaaattcc ctgagtgtta ttctacttgt attaaaaggt 742 aataatacat aatcattaaa atctgaggga tcattgccag agattgttgg ggagggaaat 802 gttatcaacg gtttcattga aattaaatcc aaaaagttat ttcctcagaa aaatcaaata 862 aagtttgcat gttttttatt cttaaaacat tttaaaaacc actgtagaat gatgtaaata 922 gggactgtgc agtatttctg acatatacta taaaattatt aaaaagtcaa tcagtattca 982 acatctttta cactaaaaag cc 1004 6 43 PRT Homo sapiens 6 Met Ala Ala Arg Ala Val Phe Leu Ala Leu Ser Ala Gln Leu Leu Gln 1 5 10 15 Ala Arg Leu Met Lys Glu Glu Ser Pro Val Val Ser Trp Arg Leu Glu 20 25 30 Pro Glu Asp Gly Thr Ala Leu Cys Phe Ile Phe 35 40 7 4193 DNA Homo sapiens CDS (101)..(3523) 7 gtggagttcg ctgcggctgt tgggggccac ctgtcttttc gcttgtgccc ctctttctag 60 tgtcgcgctc gagtcccgac gggccgctcc aagcctcgac atg tcg tac aac tac 115 Met Ser Tyr Asn Tyr 1 5 gtg gta acg gcc cag aag ccc acc gcc gtg aac ggc tgc gtg acc gga 163 Val Val Thr Ala Gln Lys Pro Thr Ala Val Asn Gly Cys Val Thr Gly 10 15 20 cac ttt act tcg gcc gaa gac tta aac ctg ttg att gcc aaa aac acg 211 His Phe Thr Ser Ala Glu Asp Leu Asn Leu Leu Ile Ala Lys Asn Thr 25 30 35 aga tta gag atc tat gtg gtc acc gcc gag ggg ctt cgg ccc gtc aaa 259 Arg Leu Glu Ile Tyr Val Val Thr Ala Glu Gly Leu Arg Pro Val Lys 40 45 50 gag gtg ggc atg tat ggg aag att gcg gtc atg gag ctt ttc agg ccc 307 Glu Val Gly Met Tyr Gly Lys Ile Ala Val Met Glu Leu Phe Arg Pro 55 60 65 aag ggg gag agc aag gac ctg ctg ttt atc ttg aca gcg aag tac aat 355 Lys Gly Glu Ser Lys Asp Leu Leu Phe Ile Leu Thr Ala Lys Tyr Asn 70 75 80 85 gcc tgc atc ctg gag tat aaa cag agt ggc gag agc att gac atc att 403 Ala Cys Ile Leu Glu Tyr Lys Gln Ser Gly Glu Ser Ile Asp Ile Ile 90 95 100 acg cga gcc cat ggc aat gtc cag gac cgc att ggc cgc ccc tca gag 451 Thr Arg Ala His Gly Asn Val Gln Asp Arg Ile Gly Arg Pro Ser Glu 105 110 115 acc ggc att att ggc atc att gac cct gag tgc cgg atg att ggc ctg 499 Thr Gly Ile Ile Gly Ile Ile Asp Pro Glu Cys Arg Met Ile Gly Leu 120 125 130 cgt ctc tat gat ggc ctt ttc aag gtt att cca cta gat cgc gat aat 547 Arg Leu Tyr Asp Gly Leu Phe Lys Val Ile Pro Leu Asp Arg Asp Asn 135 140 145 aaa gaa ctc aag gcc ttc aac atc cgc ctg gag gag ctg cat gtc att 595 Lys Glu Leu Lys Ala Phe Asn Ile Arg Leu Glu Glu Leu His Val Ile 150 155 160 165 gat gtc aag ttc cta tat ggt tgc caa gca cct act att tgc ttt gtc 643 Asp Val Lys Phe Leu Tyr Gly Cys Gln Ala Pro Thr Ile Cys Phe Val 170 175 180 tac cag gac cct cag ggg cgg cac gta aaa acc tat gag gtg tct ctc 691 Tyr Gln Asp Pro Gln Gly Arg His Val Lys Thr Tyr Glu Val Ser Leu 185 190 195 cga gaa aag gaa ttc aat aag ggc cct tgg aaa cag gaa aat gtc gaa 739 Arg Glu Lys Glu Phe Asn Lys Gly Pro Trp Lys Gln Glu Asn Val Glu 200 205 210 gct gaa gct tcc atg gtg atc gca gtc cca gag ccc ttt ggg ggg gcc 787 Ala Glu Ala Ser Met Val Ile Ala Val Pro Glu Pro Phe Gly Gly Ala 215 220 225 atc atc att gga cag gag tca atc acc tat cac aat ggt gac aaa tac 835 Ile Ile Ile Gly Gln Glu Ser Ile Thr Tyr His Asn Gly Asp Lys Tyr 230 235 240 245 ctg gct att gcc cct cct atc atc aag caa agc acg att gtg tgc cac 883 Leu Ala Ile Ala Pro Pro Ile Ile Lys Gln Ser Thr Ile Val Cys His 250 255 260 aat cga gtg gac cct aat ggc tca aga tac ctg ctg gga gac atg gaa 931 Asn Arg Val Asp Pro Asn Gly Ser Arg Tyr Leu Leu Gly Asp Met Glu 265 270 275 ggc cgg ctc ttc atg ctg ctt ttg gag aag gag gaa cag atg gat ggc 979 Gly Arg Leu Phe Met Leu Leu Leu Glu Lys Glu Glu Gln Met Asp Gly 280 285 290 acc gtc act ctc aag gat ctc cgt gta gaa ctc ctt gga gag acc tct 1027 Thr Val Thr Leu Lys Asp Leu Arg Val Glu Leu Leu Gly Glu Thr Ser 295 300 305 att gct gag tgc ttg aca tac ctt gat aat ggt gtt gtg ttt gtc ggg 1075 Ile Ala Glu Cys Leu Thr Tyr Leu Asp Asn Gly Val Val Phe Val Gly 310 315 320 325 tct cgc ctg ggt gac tcc cag ctt gtg aag ctc aac gtt gac agt aat 1123 Ser Arg Leu Gly Asp Ser Gln Leu Val Lys Leu Asn Val Asp Ser Asn 330 335 340 gaa caa ggc tcc tat gta gtg gcc atg gaa acc ttt acc aac tta gga 1171 Glu Gln Gly Ser Tyr Val Val Ala Met Glu Thr Phe Thr Asn Leu Gly 345 350 355 ccc att gtc gat atg tgc gtg gtg gac ctg gag agg cag ggg cag ggg 1219 Pro Ile Val Asp Met Cys Val Val Asp Leu Glu Arg Gln Gly Gln Gly 360 365 370 cag ctg gtc act tgc tct ggg gct ttc aag gaa ggt tct ttg cgg atc 1267 Gln Leu Val Thr Cys Ser Gly Ala Phe Lys Glu Gly Ser Leu Arg Ile 375 380 385 atc cgg aat gga att gga atc cac gag cat gcc agc att gac tta cca 1315 Ile Arg Asn Gly Ile Gly Ile His Glu His Ala Ser Ile Asp Leu Pro 390 395 400 405 ggc atc aaa gga tta tgg cca ctg cgg tct gac cct aat cgt gag act 1363 Gly Ile Lys Gly Leu Trp Pro Leu Arg Ser Asp Pro Asn Arg Glu Thr 410 415 420 gat gac act ttg gtg ctc tct ttt gtg ggc cag aca aga gtt ctc atg 1411 Asp Asp Thr Leu Val Leu Ser Phe Val Gly Gln Thr Arg Val Leu Met 425 430 435 tta aat gga gag gag gta gaa gaa acc gaa ctg atg ggt ttc gtg gat 1459 Leu Asn Gly Glu Glu Val Glu Glu Thr Glu Leu Met Gly Phe Val Asp 440 445 450 gat cag cag act ttc ttc tgt ggc aac gtg gct cat cag cag ctt atc 1507 Asp Gln Gln Thr Phe Phe Cys Gly Asn Val Ala His Gln Gln Leu Ile 455 460 465 cag atc act tca gca tcg gtg agg ttg gtc tct caa gaa ccc aaa gct 1555 Gln Ile Thr Ser Ala Ser Val Arg Leu Val Ser Gln Glu Pro Lys Ala 470 475 480 485 ctg gtc agt gaa tgg aag gag cct cag gcc aag aac atc agt gtg gcc 1603 Leu Val Ser Glu Trp Lys Glu Pro Gln Ala Lys Asn Ile Ser Val Ala 490 495 500 tcc tgc aat agc agc cag gtg gtg gtg gct gta ggc agg gcc ctc tac 1651 Ser Cys Asn Ser Ser Gln Val Val Val Ala Val Gly Arg Ala Leu Tyr 505 510 515 tat ctg cag atc cat cct cag gag ctc cgg cag atc agc cac aca gag 1699 Tyr Leu Gln Ile His Pro Gln Glu Leu Arg Gln Ile Ser His Thr Glu 520 525 530 atg gaa cat gaa gtg gct tgc ttg gac atc acc cca tta gga gac agc 1747 Met Glu His Glu Val Ala Cys Leu Asp Ile Thr Pro Leu Gly Asp Ser 535 540 545 aat gga ctg tcc cct ctt tgt gcc att ggc ctc tgg acg gac atc tcg 1795 Asn Gly Leu Ser Pro Leu Cys Ala Ile Gly Leu Trp Thr Asp Ile Ser 550 555 560 565 gct cgt atc ttg aag ttg ccc tct ttt gaa cta ctg cac aag gag atg 1843 Ala Arg Ile Leu Lys Leu Pro Ser Phe Glu Leu Leu His Lys Glu Met 570 575 580 ctg ggt gga gag atc att cct cgc tcc atc ctg atg acc acc ttt gag 1891 Leu Gly Gly Glu Ile Ile Pro Arg Ser Ile Leu Met Thr Thr Phe Glu 585 590 595 agt agc cat tac ctc ctt tgt gcc ttg gga gat gga gcg ctt ttc tac 1939 Ser Ser His Tyr Leu Leu Cys Ala Leu Gly Asp Gly Ala Leu Phe Tyr 600 605 610 ttt ggg ctc aac att gag aca ggt ctg ttg agc gac cgt aag aag gtg 1987 Phe Gly Leu Asn Ile Glu Thr Gly Leu Leu Ser Asp Arg Lys Lys Val 615 620 625 act ttg ggc acc cag ccc acc gta ttg agg act ttt cgt tct ctt tct 2035 Thr Leu Gly Thr Gln Pro Thr Val Leu Arg Thr Phe Arg Ser Leu Ser 630 635 640 645 acc acc aac gtc ttt gct tgt tct gac cgc ccc act gtc atc tat agc 2083 Thr Thr Asn Val Phe Ala Cys Ser Asp Arg Pro Thr Val Ile Tyr Ser 650 655 660 agc aac cac aaa ttg gtc ttc tca aat gtc aac ctc aag gaa gtg aac 2131 Ser Asn His Lys Leu Val Phe Ser Asn Val Asn Leu Lys Glu Val Asn 665 670 675 tac atg tgt ccc ctc aat tca gat ggc tat cct gac agc ctg gcg ctg 2179 Tyr Met Cys Pro Leu Asn Ser Asp Gly Tyr Pro Asp Ser Leu Ala Leu 680 685 690 gcc aac aat agc acc ctc acc att ggc acc atc gat gag atc cag aag 2227 Ala Asn Asn Ser Thr Leu Thr Ile Gly Thr Ile Asp Glu Ile Gln Lys 695 700 705 ctg cac att cgc aca gtt ccc ctc tat gag tct cca agg aag atc tgc 2275 Leu His Ile Arg Thr Val Pro Leu Tyr Glu Ser Pro Arg Lys Ile Cys 710 715 720 725 tac cag gaa gtg tcc cag tgt ttc ggg gtc ctc tcc agc cgc att gaa 2323 Tyr Gln Glu Val Ser Gln Cys Phe Gly Val Leu Ser Ser Arg Ile Glu 730 735 740 gtc caa gac acg agt ggg ggc acg aca gcc ttg agg ccc agc gct agc 2371 Val Gln Asp Thr Ser Gly Gly Thr Thr Ala Leu Arg Pro Ser Ala Ser 745 750 755 acc cag gct ctg tcc agc agt gta agc tcc agc aag ctg ttc tcc agc 2419 Thr Gln Ala Leu Ser Ser Ser Val Ser Ser Ser Lys Leu Phe Ser Ser 760 765 770 agc act gct cct cat gag acc tcc ttt gga gaa gag gtg gag gtg cac 2467 Ser Thr Ala Pro His Glu Thr Ser Phe Gly Glu Glu Val Glu Val His 775 780 785 aac cta ctt atc att gac caa cac acc ttt gaa gtg ctt cat gcc cac 2515 Asn Leu Leu Ile Ile Asp Gln His Thr Phe Glu Val Leu His Ala His 790 795 800 805 cag ttt ctg cag aat gaa tat gcc ctc agt ctg gtt tcc tgc aag ctg 2563 Gln Phe Leu Gln Asn Glu Tyr Ala Leu Ser Leu Val Ser Cys Lys Leu 810 815 820 ggc aaa gac ccc aac act tac ttc att gtg ggc aca gca atg gtg tat 2611 Gly Lys Asp Pro Asn Thr Tyr Phe Ile Val Gly Thr Ala Met Val Tyr 825 830 835 cct gaa gag gca gag ccc aag cag ggt cgc att gtg gtc ttt cag tat 2659 Pro Glu Glu Ala Glu Pro Lys Gln Gly Arg Ile Val Val Phe Gln Tyr 840 845 850 tcg gat gga aaa cta cag act gtg gct gaa aag gaa gtg aaa ggg gcc 2707 Ser Asp Gly Lys Leu Gln Thr Val Ala Glu Lys Glu Val Lys Gly Ala 855 860 865 gtg tac tct atg gtg gaa ttt aac ggg aag ctg tta gcc agc atc aat 2755 Val Tyr Ser Met Val Glu Phe Asn Gly Lys Leu Leu Ala Ser Ile Asn 870 875 880 885 agc acg gtg cgg ctc tat gag tgg aca aca gag aag gag ctg cgc act 2803 Ser Thr Val Arg Leu Tyr Glu Trp Thr Thr Glu Lys Glu Leu Arg Thr 890 895 900 gag tgc aac cac tac aac aac atc atg gcc ctc tac ctg aag acc aag 2851 Glu Cys Asn His Tyr Asn Asn Ile Met Ala Leu Tyr Leu Lys Thr Lys 905 910 915 ggc gac ttc atc ctg gtg ggc gac ctt atg cgc tca gtg ctg ctg ctt 2899 Gly Asp Phe Ile Leu Val Gly Asp Leu Met Arg Ser Val Leu Leu Leu 920 925 930 gcc tac aag ccc atg gaa gga aac ttt gaa gag att gct cga gac ttt 2947 Ala Tyr Lys Pro Met Glu Gly Asn Phe Glu Glu Ile Ala Arg Asp Phe 935 940 945 aat ccc aac tgg atg agt gct gtg gaa atc ttg gat gat gac aat ttt 2995 Asn Pro Asn Trp Met Ser Ala Val Glu Ile Leu Asp Asp Asp Asn Phe 950 955 960 965 ctg ggg gct gaa aat gcc ttt aac ttg ttt gtg tgt caa aag gat agc 3043 Leu Gly Ala Glu Asn Ala Phe Asn Leu Phe Val Cys Gln Lys Asp Ser 970 975 980 gct gcc acc act gac gag gag cgg cag cac ctc cag gag gtt ggt ctt 3091 Ala Ala Thr Thr Asp Glu Glu Arg Gln His Leu Gln Glu Val Gly Leu 985 990 995 ttc cac ctg ggc gag ttt gtc aat gtc ttt tgc cac ggc tct ctg 3136 Phe His Leu Gly Glu Phe Val Asn Val Phe Cys His Gly Ser Leu 1000 1005 1010 gta atg cag aat ctg ggt gag act tcc acc ccc aca caa ggc tcg 3181 Val Met Gln Asn Leu Gly Glu Thr Ser Thr Pro Thr Gln Gly Ser 1015 1020 1025 gtg ctc ttc ggc acg gtc aac ggc atg ata ggg ctg gtg acc tca 3226 Val Leu Phe Gly Thr Val Asn Gly Met Ile Gly Leu Val Thr Ser 1030 1035 1040 ctg tca gag agc tgg tac aac ctc ctg ctg gac atg cag aat cga 3271 Leu Ser Glu Ser Trp Tyr Asn Leu Leu Leu Asp Met Gln Asn Arg 1045 1050 1055 ctc aat aaa gtc atc aaa agt gtg ggg aag atc gag cac tcc ttc 3316 Leu Asn Lys Val Ile Lys Ser Val Gly Lys Ile Glu His Ser Phe 1060 1065 1070 tgg aga tcc ttt cac acc gag cgg aag aca gaa cca gcc aca ggt 3361 Trp Arg Ser Phe His Thr Glu Arg Lys Thr Glu Pro Ala Thr Gly 1075 1080 1085 ttc atc gac ggt gac ttg att gag agt ttc ctg gat att agc cgc 3406 Phe Ile Asp Gly Asp Leu Ile Glu Ser Phe Leu Asp Ile Ser Arg 1090 1095 1100 ccc aag atg cag gag gtg gtg gca aac cta cag tat gac gat ggc 3451 Pro Lys Met Gln Glu Val Val Ala Asn Leu Gln Tyr Asp Asp Gly 1105 1110 1115 agc ggt atg aag cga gag gcc act gca gac gac ctc atc aag gtt 3496 Ser Gly Met Lys Arg Glu Ala Thr Ala Asp Asp Leu Ile Lys Val 1120 1125 1130 gtg gag gag cta act cgg atc cat tag ccaagggcag ggggccccct 3543 Val Glu Glu Leu Thr Arg Ile His 1135 1140 ttctgaccct ccccaaaggc tttgccctgc tgccctcccc ctcctctcca ccatcgtctt 3603 cttggccatg ggaggccttt ccctaagcca gctgccccca gagccacagt tcccctatgt 3663 ggaagtgggg cgggcttcat agagacttgg gaatgagctg aaggtgaaac attttctccc 3723 tggattttta ccagtctcac atgattccag ccatcacctt agaccaccaa gccttgattg 3783 gtgttgccag ttgtcctcct tccggggaag gattttgcag ttctttggct gaaaggaagc 3843 tgtgcgtgtg tgtgtgtgta tgtgtgtgtg tgtatgtgta tctcacactc atgcaatgtc 3903 ctctttttat ttagattggc agtgtaggga gttgtgggta gtggggaaga gggttaggag 3963 ggtttcattg tctgtgaagt gagaccttcc ttttactttt cttctattgc ctctgagagc 4023 atcagcctag aggcctgact gccaagccat gggtagcctg ggtgtaaaac ctggagatgg 4083 tggatgatcc ccacgccaca gcccttttgt ctctgcaaac tgccttcttc ggaaagaaga 4143 aggtgggagg atgtgaattg ttagtttctg agttttacca aataaagtag 4193 8 1140 PRT Homo sapiens 8 Met Ser Tyr Asn Tyr Val Val Thr Ala Gln Lys Pro Thr Ala Val Asn 1 5 10 15 Gly Cys Val Thr Gly His Phe Thr Ser Ala Glu Asp Leu Asn Leu Leu 20 25 30 Ile Ala Lys Asn Thr Arg Leu Glu Ile Tyr Val Val Thr Ala Glu Gly 35 40 45 Leu Arg Pro Val Lys Glu Val Gly Met Tyr Gly Lys Ile Ala Val Met 50 55 60 Glu Leu Phe Arg Pro Lys Gly Glu Ser Lys Asp Leu Leu Phe Ile Leu 65 70 75 80 Thr Ala Lys Tyr Asn Ala Cys Ile Leu Glu Tyr Lys Gln Ser Gly Glu 85 90 95 Ser Ile Asp Ile Ile Thr Arg Ala His Gly Asn Val Gln Asp Arg Ile 100 105 110 Gly Arg Pro Ser Glu Thr Gly Ile Ile Gly Ile Ile Asp Pro Glu Cys 115 120 125 Arg Met Ile Gly Leu Arg Leu Tyr Asp Gly Leu Phe Lys Val Ile Pro 130 135 140 Leu Asp Arg Asp Asn Lys Glu Leu Lys Ala Phe Asn Ile Arg Leu Glu 145 150 155 160 Glu Leu His Val Ile Asp Val Lys Phe Leu Tyr Gly Cys Gln Ala Pro 165 170 175 Thr Ile Cys Phe Val Tyr Gln Asp Pro Gln Gly Arg His Val Lys Thr 180 185 190 Tyr Glu Val Ser Leu Arg Glu Lys Glu Phe Asn Lys Gly Pro Trp Lys 195 200 205 Gln Glu Asn Val Glu Ala Glu Ala Ser Met Val Ile Ala Val Pro Glu 210 215 220 Pro Phe Gly Gly Ala Ile Ile Ile Gly Gln Glu Ser Ile Thr Tyr His 225 230 235 240 Asn Gly Asp Lys Tyr Leu Ala Ile Ala Pro Pro Ile Ile Lys Gln Ser 245 250 255 Thr Ile Val Cys His Asn Arg Val Asp Pro Asn Gly Ser Arg Tyr Leu 260 265 270 Leu Gly Asp Met Glu Gly Arg Leu Phe Met Leu Leu Leu Glu Lys Glu 275 280 285 Glu Gln Met Asp Gly Thr Val Thr Leu Lys Asp Leu Arg Val Glu Leu 290 295 300 Leu Gly Glu Thr Ser Ile Ala Glu Cys Leu Thr Tyr Leu Asp Asn Gly 305 310 315 320 Val Val Phe Val Gly Ser Arg Leu Gly Asp Ser Gln Leu Val Lys Leu 325 330 335 Asn Val Asp Ser Asn Glu Gln Gly Ser Tyr Val Val Ala Met Glu Thr 340 345 350 Phe Thr Asn Leu Gly Pro Ile Val Asp Met Cys Val Val Asp Leu Glu 355 360 365 Arg Gln Gly Gln Gly Gln Leu Val Thr Cys Ser Gly Ala Phe Lys Glu 370 375 380 Gly Ser Leu Arg Ile Ile Arg Asn Gly Ile Gly Ile His Glu His Ala 385 390 395 400 Ser Ile Asp Leu Pro Gly Ile Lys Gly Leu Trp Pro Leu Arg Ser Asp 405 410 415 Pro Asn Arg Glu Thr Asp Asp Thr Leu Val Leu Ser Phe Val Gly Gln 420 425 430 Thr Arg Val Leu Met Leu Asn Gly Glu Glu Val Glu Glu Thr Glu Leu 435 440 445 Met Gly Phe Val Asp Asp Gln Gln Thr Phe Phe Cys Gly Asn Val Ala 450 455 460 His Gln Gln Leu Ile Gln Ile Thr Ser Ala Ser Val Arg Leu Val Ser 465 470 475 480 Gln Glu Pro Lys Ala Leu Val Ser Glu Trp Lys Glu Pro Gln Ala Lys 485 490 495 Asn Ile Ser Val Ala Ser Cys Asn Ser Ser Gln Val Val Val Ala Val 500 505 510 Gly Arg Ala Leu Tyr Tyr Leu Gln Ile His Pro Gln Glu Leu Arg Gln 515 520 525 Ile Ser His Thr Glu Met Glu His Glu Val Ala Cys Leu Asp Ile Thr 530 535 540 Pro Leu Gly Asp Ser Asn Gly Leu Ser Pro Leu Cys Ala Ile Gly Leu 545 550 555 560 Trp Thr Asp Ile Ser Ala Arg Ile Leu Lys Leu Pro Ser Phe Glu Leu 565 570 575 Leu His Lys Glu Met Leu Gly Gly Glu Ile Ile Pro Arg Ser Ile Leu 580 585 590 Met Thr Thr Phe Glu Ser Ser His Tyr Leu Leu Cys Ala Leu Gly Asp 595 600 605 Gly Ala Leu Phe Tyr Phe Gly Leu Asn Ile Glu Thr Gly Leu Leu Ser 610 615 620 Asp Arg Lys Lys Val Thr Leu Gly Thr Gln Pro Thr Val Leu Arg Thr 625 630 635 640 Phe Arg Ser Leu Ser Thr Thr Asn Val Phe Ala Cys Ser Asp Arg Pro 645 650 655 Thr Val Ile Tyr Ser Ser Asn His Lys Leu Val Phe Ser Asn Val Asn 660 665 670 Leu Lys Glu Val Asn Tyr Met Cys Pro Leu Asn Ser Asp Gly Tyr Pro 675 680 685 Asp Ser Leu Ala Leu Ala Asn Asn Ser Thr Leu Thr Ile Gly Thr Ile 690 695 700 Asp Glu Ile Gln Lys Leu His Ile Arg Thr Val Pro Leu Tyr Glu Ser 705 710 715 720 Pro Arg Lys Ile Cys Tyr Gln Glu Val Ser Gln Cys Phe Gly Val Leu 725 730 735 Ser Ser Arg Ile Glu Val Gln Asp Thr Ser Gly Gly Thr Thr Ala Leu 740 745 750 Arg Pro Ser Ala Ser Thr Gln Ala Leu Ser Ser Ser Val Ser Ser Ser 755 760 765 Lys Leu Phe Ser Ser Ser Thr Ala Pro His Glu Thr Ser Phe Gly Glu 770 775 780 Glu Val Glu Val His Asn Leu Leu Ile Ile Asp Gln His Thr Phe Glu 785 790 795 800 Val Leu His Ala His Gln Phe Leu Gln Asn Glu Tyr Ala Leu Ser Leu 805 810 815 Val Ser Cys Lys Leu Gly Lys Asp Pro Asn Thr Tyr Phe Ile Val Gly 820 825 830 Thr Ala Met Val Tyr Pro Glu Glu Ala Glu Pro Lys Gln Gly Arg Ile 835 840 845 Val Val Phe Gln Tyr Ser Asp Gly Lys Leu Gln Thr Val Ala Glu Lys 850 855 860 Glu Val Lys Gly Ala Val Tyr Ser Met Val Glu Phe Asn Gly Lys Leu 865 870 875 880 Leu Ala Ser Ile Asn Ser Thr Val Arg Leu Tyr Glu Trp Thr Thr Glu 885 890 895 Lys Glu Leu Arg Thr Glu Cys Asn His Tyr Asn Asn Ile Met Ala Leu 900 905 910 Tyr Leu Lys Thr Lys Gly Asp Phe Ile Leu Val Gly Asp Leu Met Arg 915 920 925 Ser Val Leu Leu Leu Ala Tyr Lys Pro Met Glu Gly Asn Phe Glu Glu 930 935 940 Ile Ala Arg Asp Phe Asn Pro Asn Trp Met Ser Ala Val Glu Ile Leu 945 950 955 960 Asp Asp Asp Asn Phe Leu Gly Ala Glu Asn Ala Phe Asn Leu Phe Val 965 970 975 Cys Gln Lys Asp Ser Ala Ala Thr Thr Asp Glu Glu Arg Gln His Leu 980 985 990 Gln Glu Val Gly Leu Phe His Leu Gly Glu Phe Val Asn Val Phe Cys 995 1000 1005 His Gly Ser Leu Val Met Gln Asn Leu Gly Glu Thr Ser Thr Pro 1010 1015 1020 Thr Gln Gly Ser Val Leu Phe Gly Thr Val Asn Gly Met Ile Gly 1025 1030 1035 Leu Val Thr Ser Leu Ser Glu Ser Trp Tyr Asn Leu Leu Leu Asp 1040 1045 1050 Met Gln Asn Arg Leu Asn Lys Val Ile Lys Ser Val Gly Lys Ile 1055 1060 1065 Glu His Ser Phe Trp Arg Ser Phe His Thr Glu Arg Lys Thr Glu 1070 1075 1080 Pro Ala Thr Gly Phe Ile Asp Gly Asp Leu Ile Glu Ser Phe Leu 1085 1090 1095 Asp Ile Ser Arg Pro Lys Met Gln Glu Val Val Ala Asn Leu Gln 1100 1105 1110 Tyr Asp Asp Gly Ser Gly Met Lys Arg Glu Ala Thr Ala Asp Asp 1115 1120 1125 Leu Ile Lys Val Val Glu Glu Leu Thr Arg Ile His 1130 1135 1140 9 2269 DNA Homo sapiens CDS (292)..(1701) 9 ccgtttcctc ccctcccctc cactcggccg tccctccttc ctcctccctc ctccctcctc 60 ctcccgctcc tgaagagcgc gccgcgtggg ggacggcccg gttacttcct ccagagactg 120 acgagtgcgg tgtcgctcca gctcagagct cccggagccg cccggccagc gtccggcctc 180 cctgatcgtc tctggccggc gccctcgccc tcgcccggcg cgcaccgagc agccgcgggc 240 gccgagcagc caccgtcccg accaagcgcc ggccctgccc gcagcggcag g atg aat 297 Met Asn 1 gat ttc gga atc aag aat atg gac cag gta gcc cct gtg gct aac agt 345 Asp Phe Gly Ile Lys Asn Met Asp Gln Val Ala Pro Val Ala Asn Ser 5 10 15 tac aga ggg aca ctc aag cgc cag cca gcc ttt gac acc ttt gat ggg 393 Tyr Arg Gly Thr Leu Lys Arg Gln Pro Ala Phe Asp Thr Phe Asp Gly 20 25 30 tcc ctg ttt gct gtt ttt cct tct cta aat gaa gag caa aca ctg caa 441 Ser Leu Phe Ala Val Phe Pro Ser Leu Asn Glu Glu Gln Thr Leu Gln 35 40 45 50 gaa gtg cca aca ggc ttg gat tcc att tct cat gac tcc gcc aac tgt 489 Glu Val Pro Thr Gly Leu Asp Ser Ile Ser His Asp Ser Ala Asn Cys 55 60 65 gaa ttg cct ttg tta acc ccg tgc agc aag gct gtg atg agt caa gcc 537 Glu Leu Pro Leu Leu Thr Pro Cys Ser Lys Ala Val Met Ser Gln Ala 70 75 80 tta aaa gct acc ttc agt ggc ttc aaa aag gaa cag cgg cgc ctg ggc 585 Leu Lys Ala Thr Phe Ser Gly Phe Lys Lys Glu Gln Arg Arg Leu Gly 85 90 95 att cca aag aac ccc tgg ctg tgg agt gag caa cag gta tgc cag tgg 633 Ile Pro Lys Asn Pro Trp Leu Trp Ser Glu Gln Gln Val Cys Gln Trp 100 105 110 ctt ctc tgg gcc acc aat gag ttc agt ctg gtg aac gtg aat ctg cag 681 Leu Leu Trp Ala Thr Asn Glu Phe Ser Leu Val Asn Val Asn Leu Gln 115 120 125 130 agg ttc ggc atg aat ggc cag atg ctg tgt aac ctt ggc aag gaa cgc 729 Arg Phe Gly Met Asn Gly Gln Met Leu Cys Asn Leu Gly Lys Glu Arg 135 140 145 ttt ctg gag ctg gca cct gac ttt gtg ggt gac att ctc tgg gaa cat 777 Phe Leu Glu Leu Ala Pro Asp Phe Val Gly Asp Ile Leu Trp Glu His 150 155 160 ctg gag caa atg atc aaa gaa aac caa gaa aag aca gaa gat caa tat 825 Leu Glu Gln Met Ile Lys Glu Asn Gln Glu Lys Thr Glu Asp Gln Tyr 165 170 175 gaa gaa aat tca cac ctc acc tcc gtt cct cat tgg att aac agc aat 873 Glu Glu Asn Ser His Leu Thr Ser Val Pro His Trp Ile Asn Ser Asn 180 185 190 aca tta ggt ttt ggc aca gag cag gcg ccc tat gga atg cag aca cag 921 Thr Leu Gly Phe Gly Thr Glu Gln Ala Pro Tyr Gly Met Gln Thr Gln 195 200 205 210 aat tac ccc aaa ggc ggc ctc ctg gac agc atg tgt ccg gcc tcc aca 969 Asn Tyr Pro Lys Gly Gly Leu Leu Asp Ser Met Cys Pro Ala Ser Thr 215 220 225 ccc agc gta ctc agc tct gag cag gag ttt cag atg ttc ccc aag tct 1017 Pro Ser Val Leu Ser Ser Glu Gln Glu Phe Gln Met Phe Pro Lys Ser 230 235 240 cgg ctc agc tcc gtc agc gtc acc tac tgc tct gtc agt cag gac ttc 1065 Arg Leu Ser Ser Val Ser Val Thr Tyr Cys Ser Val Ser Gln Asp Phe 245 250 255 cca ggc agc aac ttg aat ttg ctc acc aac aat tct ggg act ccc aaa 1113 Pro Gly Ser Asn Leu Asn Leu Leu Thr Asn Asn Ser Gly Thr Pro Lys 260 265 270 gac cac gac tcc cct gag aac ggt gcg gac agc ttc gag agc tca gac 1161 Asp His Asp Ser Pro Glu Asn Gly Ala Asp Ser Phe Glu Ser Ser Asp 275 280 285 290 tcc ctc ctc cag tcc tgg aac agc cag tcg tcc ttg ctg gat gtg caa 1209 Ser Leu Leu Gln Ser Trp Asn Ser Gln Ser Ser Leu Leu Asp Val Gln 295 300 305 cgg gtt cct tcc ttc gag agc ttc gaa gat gac tgc agc cag tct ctc 1257 Arg Val Pro Ser Phe Glu Ser Phe Glu Asp Asp Cys Ser Gln Ser Leu 310 315 320 tgc ctc aat aag cca acc atg tct ttc aag gat tac atc caa gag agg 1305 Cys Leu Asn Lys Pro Thr Met Ser Phe Lys Asp Tyr Ile Gln Glu Arg 325 330 335 agt gac cca gtg gag caa ggc aaa cca gtt ata cct gca gct gtg ctg 1353 Ser Asp Pro Val Glu Gln Gly Lys Pro Val Ile Pro Ala Ala Val Leu 340 345 350 gcc ggc ttc aca gga agt gga cct att cag ctg tgg cag ttt ctc ctg 1401 Ala Gly Phe Thr Gly Ser Gly Pro Ile Gln Leu Trp Gln Phe Leu Leu 355 360 365 370 gag ctg cta tca gac aaa tcc tgc cag tca ttc atc agc tgg act gga 1449 Glu Leu Leu Ser Asp Lys Ser Cys Gln Ser Phe Ile Ser Trp Thr Gly 375 380 385 gac gga tgg gag ttt aag ctc gcc gac ccc gat gag gtg gcc cgc cgg 1497 Asp Gly Trp Glu Phe Lys Leu Ala Asp Pro Asp Glu Val Ala Arg Arg 390 395 400 tgg gga aag agg aaa aat aag ccc aag atg aac tac gag aag ctg agc 1545 Trp Gly Lys Arg Lys Asn Lys Pro Lys Met Asn Tyr Glu Lys Leu Ser 405 410 415 cgg ggc tta cgc tac tat tac gac aag aac atc atc cac aag acg tcg 1593 Arg Gly Leu Arg Tyr Tyr Tyr Asp Lys Asn Ile Ile His Lys Thr Ser 420 425 430 ggg aag cgc tac gtg tac cgc ttc gtg tgc gac ctc cag aac ttg ctg 1641 Gly Lys Arg Tyr Val Tyr Arg Phe Val Cys Asp Leu Gln Asn Leu Leu 435 440 445 450 ggg ttc acg ccc gag gaa ctg cac gcc atc ctg ggc gtc cag ccc gac 1689 Gly Phe Thr Pro Glu Glu Leu His Ala Ile Leu Gly Val Gln Pro Asp 455 460 465 acg gag gac tga ggtcgccggg accaccctga gccggcccca ggctcgtgga 1741 Thr Glu Asp ctgagtggga agcccatcct gaccagctgc ctccgaggac ccaggaaagg caggattgaa 1801 aatgtccagg aaagtggcca agaagcagtg gccttattgc atcccaaacc acgcctcttg 1861 accaggctgc ctcccttgtg gcagcaacgg cacagctaat tctactcaca gtgcttttaa 1921 gtgaaaatgg tcgagaaaga ggcaccggga agccgtcctg gcgcctggca gtccgtggga 1981 cgggatggtt ctggctgttt gagattctca aaggagcgag catgtcgtgg acacacacag 2041 actattttta gattttcttt tgccttttgc aaccaggaac agcaaatgca aaaactcttt 2101 gagagggtag gagggtggga aggaaacaac catgtcattt cagaagttag tttgtatata 2161 ttataataat cttataattg ttctcagaat cccttaacag ttgtatttaa cagaaattgt 2221 atattgtaat ttaaaataat tatataactg tatttgaaat aagaattc 2269 10 469 PRT Homo sapiens 10 Met Asn Asp Phe Gly Ile Lys Asn Met Asp Gln Val Ala Pro Val Ala 1 5 10 15 Asn Ser Tyr Arg Gly Thr Leu Lys Arg Gln Pro Ala Phe Asp Thr Phe 20 25 30 Asp Gly Ser Leu Phe Ala Val Phe Pro Ser Leu Asn Glu Glu Gln Thr 35 40 45 Leu Gln Glu Val Pro Thr Gly Leu Asp Ser Ile Ser His Asp Ser Ala 50 55 60 Asn Cys Glu Leu Pro Leu Leu Thr Pro Cys Ser Lys Ala Val Met Ser 65 70 75 80 Gln Ala Leu Lys Ala Thr Phe Ser Gly Phe Lys Lys Glu Gln Arg Arg 85 90 95 Leu Gly Ile Pro Lys Asn Pro Trp Leu Trp Ser Glu Gln Gln Val Cys 100 105 110 Gln Trp Leu Leu Trp Ala Thr Asn Glu Phe Ser Leu Val Asn Val Asn 115 120 125 Leu Gln Arg Phe Gly Met Asn Gly Gln Met Leu Cys Asn Leu Gly Lys 130 135 140 Glu Arg Phe Leu Glu Leu Ala Pro Asp Phe Val Gly Asp Ile Leu Trp 145 150 155 160 Glu His Leu Glu Gln Met Ile Lys Glu Asn Gln Glu Lys Thr Glu Asp 165 170 175 Gln Tyr Glu Glu Asn Ser His Leu Thr Ser Val Pro His Trp Ile Asn 180 185 190 Ser Asn Thr Leu Gly Phe Gly Thr Glu Gln Ala Pro Tyr Gly Met Gln 195 200 205 Thr Gln Asn Tyr Pro Lys Gly Gly Leu Leu Asp Ser Met Cys Pro Ala 210 215 220 Ser Thr Pro Ser Val Leu Ser Ser Glu Gln Glu Phe Gln Met Phe Pro 225 230 235 240 Lys Ser Arg Leu Ser Ser Val Ser Val Thr Tyr Cys Ser Val Ser Gln 245 250 255 Asp Phe Pro Gly Ser Asn Leu Asn Leu Leu Thr Asn Asn Ser Gly Thr 260 265 270 Pro Lys Asp His Asp Ser Pro Glu Asn Gly Ala Asp Ser Phe Glu Ser 275 280 285 Ser Asp Ser Leu Leu Gln Ser Trp Asn Ser Gln Ser Ser Leu Leu Asp 290 295 300 Val Gln Arg Val Pro Ser Phe Glu Ser Phe Glu Asp Asp Cys Ser Gln 305 310 315 320 Ser Leu Cys Leu Asn Lys Pro Thr Met Ser Phe Lys Asp Tyr Ile Gln 325 330 335 Glu Arg Ser Asp Pro Val Glu Gln Gly Lys Pro Val Ile Pro Ala Ala 340 345 350 Val Leu Ala Gly Phe Thr Gly Ser Gly Pro Ile Gln Leu Trp Gln Phe 355 360 365 Leu Leu Glu Leu Leu Ser Asp Lys Ser Cys Gln Ser Phe Ile Ser Trp 370 375 380 Thr Gly Asp Gly Trp Glu Phe Lys Leu Ala Asp Pro Asp Glu Val Ala 385 390 395 400 Arg Arg Trp Gly Lys Arg Lys Asn Lys Pro Lys Met Asn Tyr Glu Lys 405 410 415 Leu Ser Arg Gly Leu Arg Tyr Tyr Tyr Asp Lys Asn Ile Ile His Lys 420 425 430 Thr Ser Gly Lys Arg Tyr Val Tyr Arg Phe Val Cys Asp Leu Gln Asn 435 440 445 Leu Leu Gly Phe Thr Pro Glu Glu Leu His Ala Ile Leu Gly Val Gln 450 455 460 Pro Asp Thr Glu Asp 465 11 1533 DNA Homo sapiens CDS (1)..(1533) 11 atg gcg gcg gag ctg gtg gag gcc aaa aac atg gtg atg agt ttt cga 48 Met Ala Ala Glu Leu Val Glu Ala Lys Asn Met Val Met Ser Phe Arg 1 5 10 15 gtc tcc gac ctt cag atg ctc ctg ggt ttc gtg ggc cgg agt aag agt 96 Val Ser Asp Leu Gln Met Leu Leu Gly Phe Val Gly Arg Ser Lys Ser 20 25 30 gga ctg aag cac gag ctc gtc acc agg gcc ctc cag ctg gtg cag ttt 144 Gly Leu Lys His Glu Leu Val Thr Arg Ala Leu Gln Leu Val Gln Phe 35 40 45 gac tgt agc cct gag ctg ttc aag aag atc aag gag ctg tac gag acc 192 Asp Cys Ser Pro Glu Leu Phe Lys Lys Ile Lys Glu Leu Tyr Glu Thr 50 55 60 cgc tac gcc aag aag aac tcg gag cct gcc cca cag ccg cac cgg ccc 240 Arg Tyr Ala Lys Lys Asn Ser Glu Pro Ala Pro Gln Pro His Arg Pro 65 70 75 80 ctg gac ccc ctg acc atg cac tcc acc tac gac cgg gcc ggc gct gtg 288 Leu Asp Pro Leu Thr Met His Ser Thr Tyr Asp Arg Ala Gly Ala Val 85 90 95 ccc agg act ccg ctg gca ggc ccc aat att gac tac ccc gtg ctc tac 336 Pro Arg Thr Pro Leu Ala Gly Pro Asn Ile Asp Tyr Pro Val Leu Tyr 100 105 110 gga aag tac tta aac gga ctg gga cgg ttg ccc gcc aag acc ctc aag 384 Gly Lys Tyr Leu Asn Gly Leu Gly Arg Leu Pro Ala Lys Thr Leu Lys 115 120 125 cca gaa gtc cgc ctg gtg aag ctg ccg ttc ttt aat atg ctg gat gag 432 Pro Glu Val Arg Leu Val Lys Leu Pro Phe Phe Asn Met Leu Asp Glu 130 135 140 ctg ctg aag ccc acc gaa tta gtc cca cag aac aac gag aag ctt cag 480 Leu Leu Lys Pro Thr Glu Leu Val Pro Gln Asn Asn Glu Lys Leu Gln 145 150 155 160 gag agc ccg tgc atc ttc gca ttg acg cca aga cag gtg gag ttg atc 528 Glu Ser Pro Cys Ile Phe Ala Leu Thr Pro Arg Gln Val Glu Leu Ile 165 170 175 cgg aaa ttc cag gga atg cag ccc gga gtt aaa gcc gtg cag gtc gtc 576 Arg Lys Phe Gln Gly Met Gln Pro Gly Val Lys Ala Val Gln Val Val 180 185 190 ctg aga atc tgt tac tca gac acc agc tgc cct cag gag gac cag tac 624 Leu Arg Ile Cys Tyr Ser Asp Thr Ser Cys Pro Gln Glu Asp Gln Tyr 195 200 205 ccg ccc aac atc gct gtg aag gtc aac cac agc tac tgc tcc gtc ccg 672 Pro Pro Asn Ile Ala Val Lys Val Asn His Ser Tyr Cys Ser Val Pro 210 215 220 ggc tac tac ccc tcc aat aag ccc ggg gtg gag ccc aag agg ccg tgc 720 Gly Tyr Tyr Pro Ser Asn Lys Pro Gly Val Glu Pro Lys Arg Pro Cys 225 230 235 240 cgc ccc atc aac ctc act cac ctc atg tac ctg tcc tcg gcc acc aac 768 Arg Pro Ile Asn Leu Thr His Leu Met Tyr Leu Ser Ser Ala Thr Asn 245 250 255 cgc atc act gtc acc tgg ggg aac tac ggc aag agc tac tcg gtg gcc 816 Arg Ile Thr Val Thr Trp Gly Asn Tyr Gly Lys Ser Tyr Ser Val Ala 260 265 270 ctg tac ctg gtg cgg cag ctg acc tca tcg gag ctg ctg cag agg ctg 864 Leu Tyr Leu Val Arg Gln Leu Thr Ser Ser Glu Leu Leu Gln Arg Leu 275 280 285 aag acc att ggg gta aag cac ccg gag ctg tgc aag gca ctg gtc aag 912 Lys Thr Ile Gly Val Lys His Pro Glu Leu Cys Lys Ala Leu Val Lys 290 295 300 gag aag ctg cgc ctt gat cct gac agc gag atc gcc acc acc ggt gtg 960 Glu Lys Leu Arg Leu Asp Pro Asp Ser Glu Ile Ala Thr Thr Gly Val 305 310 315 320 cgg gtg tcc ctc atc tgt ccg ctg gtg aag atg cgg ctc tcc gtg ccc 1008 Arg Val Ser Leu Ile Cys Pro Leu Val Lys Met Arg Leu Ser Val Pro 325 330 335 tgc cgg gca gaa acc tgc gcc cac ctg cag tgc ttc gac gcc gtc ttc 1056 Cys Arg Ala Glu Thr Cys Ala His Leu Gln Cys Phe Asp Ala Val Phe 340 345 350 tac ctg cag atg aac gag aag aag ccc acc tgg atg tgc ccc gtg tgc 1104 Tyr Leu Gln Met Asn Glu Lys Lys Pro Thr Trp Met Cys Pro Val Cys 355 360 365 gac aag cca gcc ccc tac gac cag ctc atc atc gac ggg ctc ctc tcg 1152 Asp Lys Pro Ala Pro Tyr Asp Gln Leu Ile Ile Asp Gly Leu Leu Ser 370 375 380 aag atc ctg agc gag tgt gag gac gcc gac gag atc gag tac ctg gtg 1200 Lys Ile Leu Ser Glu Cys Glu Asp Ala Asp Glu Ile Glu Tyr Leu Val 385 390 395 400 gac ggc tcg tgg tgc ccg atc cgc gcc gaa aag gag cgc agc tgc agc 1248 Asp Gly Ser Trp Cys Pro Ile Arg Ala Glu Lys Glu Arg Ser Cys Ser 405 410 415 ccg cag ggc gcc atc ctc gtg ctg ggc ccc tcg gac gcc aat ggg ctc 1296 Pro Gln Gly Ala Ile Leu Val Leu Gly Pro Ser Asp Ala Asn Gly Leu 420 425 430 ctg ccc gcc ccc agc gtc aac ggg agc ggt gcc ctg ggc agc acg ggt 1344 Leu Pro Ala Pro Ser Val Asn Gly Ser Gly Ala Leu Gly Ser Thr Gly 435 440 445 ggc ggc ggc ccg gtg ggc agc atg gag aat ggg aag ccg ggc gcc gat 1392 Gly Gly Gly Pro Val Gly Ser Met Glu Asn Gly Lys Pro Gly Ala Asp 450 455 460 gtg gtg gac ctc acg ctg gac agc tca tcg tcc tcg gag gat gag gag 1440 Val Val Asp Leu Thr Leu Asp Ser Ser Ser Ser Ser Glu Asp Glu Glu 465 470 475 480 gag gag gaa gag gag gag gaa gac gag gac gaa gag ggg ccc cgg ccc 1488 Glu Glu Glu Glu Glu Glu Glu Asp Glu Asp Glu Glu Gly Pro Arg Pro 485 490 495 aag cgc cgc tgc ccc ttc cag aag ggc ctg gtg ccg gcc tgc tga 1533 Lys Arg Arg Cys Pro Phe Gln Lys Gly Leu Val Pro Ala Cys 500 505 510 12 510 PRT Homo sapiens 12 Met Ala Ala Glu Leu Val Glu Ala Lys Asn Met Val Met Ser Phe Arg 1 5 10 15 Val Ser Asp Leu Gln Met Leu Leu Gly Phe Val Gly Arg Ser Lys Ser 20 25 30 Gly Leu Lys His Glu Leu Val Thr Arg Ala Leu Gln Leu Val Gln Phe 35 40 45 Asp Cys Ser Pro Glu Leu Phe Lys Lys Ile Lys Glu Leu Tyr Glu Thr 50 55 60 Arg Tyr Ala Lys Lys Asn Ser Glu Pro Ala Pro Gln Pro His Arg Pro 65 70 75 80 Leu Asp Pro Leu Thr Met His Ser Thr Tyr Asp Arg Ala Gly Ala Val 85 90 95 Pro Arg Thr Pro Leu Ala Gly Pro Asn Ile Asp Tyr Pro Val Leu Tyr 100 105 110 Gly Lys Tyr Leu Asn Gly Leu Gly Arg Leu Pro Ala Lys Thr Leu Lys 115 120 125 Pro Glu Val Arg Leu Val Lys Leu Pro Phe Phe Asn Met Leu Asp Glu 130 135 140 Leu Leu Lys Pro Thr Glu Leu Val Pro Gln Asn Asn Glu Lys Leu Gln 145 150 155 160 Glu Ser Pro Cys Ile Phe Ala Leu Thr Pro Arg Gln Val Glu Leu Ile 165 170 175 Arg Lys Phe Gln Gly Met Gln Pro Gly Val Lys Ala Val Gln Val Val 180 185 190 Leu Arg Ile Cys Tyr Ser Asp Thr Ser Cys Pro Gln Glu Asp Gln Tyr 195 200 205 Pro Pro Asn Ile Ala Val Lys Val Asn His Ser Tyr Cys Ser Val Pro 210 215 220 Gly Tyr Tyr Pro Ser Asn Lys Pro Gly Val Glu Pro Lys Arg Pro Cys 225 230 235 240 Arg Pro Ile Asn Leu Thr His Leu Met Tyr Leu Ser Ser Ala Thr Asn 245 250 255 Arg Ile Thr Val Thr Trp Gly Asn Tyr Gly Lys Ser Tyr Ser Val Ala 260 265 270 Leu Tyr Leu Val Arg Gln Leu Thr Ser Ser Glu Leu Leu Gln Arg Leu 275 280 285 Lys Thr Ile Gly Val Lys His Pro Glu Leu Cys Lys Ala Leu Val Lys 290 295 300 Glu Lys Leu Arg Leu Asp Pro Asp Ser Glu Ile Ala Thr Thr Gly Val 305 310 315 320 Arg Val Ser Leu Ile Cys Pro Leu Val Lys Met Arg Leu Ser Val Pro 325 330 335 Cys Arg Ala Glu Thr Cys Ala His Leu Gln Cys Phe Asp Ala Val Phe 340 345 350 Tyr Leu Gln Met Asn Glu Lys Lys Pro Thr Trp Met Cys Pro Val Cys 355 360 365 Asp Lys Pro Ala Pro Tyr Asp Gln Leu Ile Ile Asp Gly Leu Leu Ser 370 375 380 Lys Ile Leu Ser Glu Cys Glu Asp Ala Asp Glu Ile Glu Tyr Leu Val 385 390 395 400 Asp Gly Ser Trp Cys Pro Ile Arg Ala Glu Lys Glu Arg Ser Cys Ser 405 410 415 Pro Gln Gly Ala Ile Leu Val Leu Gly Pro Ser Asp Ala Asn Gly Leu 420 425 430 Leu Pro Ala Pro Ser Val Asn Gly Ser Gly Ala Leu Gly Ser Thr Gly 435 440 445 Gly Gly Gly Pro Val Gly Ser Met Glu Asn Gly Lys Pro Gly Ala Asp 450 455 460 Val Val Asp Leu Thr Leu Asp Ser Ser Ser Ser Ser Glu Asp Glu Glu 465 470 475 480 Glu Glu Glu Glu Glu Glu Glu Asp Glu Asp Glu Glu Gly Pro Arg Pro 485 490 495 Lys Arg Arg Cys Pro Phe Gln Lys Gly Leu Val Pro Ala Cys 500 505 510 13 1719 DNA Homo sapiens CDS (1)..(1719) 13 atg gcg gat ttc gaa gag ttg agg aat atg gtt tct agt ttt agg gtt 48 Met Ala Asp Phe Glu Glu Leu Arg Asn Met Val Ser Ser Phe Arg Val 1 5 10 15 tct gaa cta caa gta tta cta ggc ttt gct gga cgg aat aaa agt gga 96 Ser Glu Leu Gln Val Leu Leu Gly Phe Ala Gly Arg Asn Lys Ser Gly 20 25 30 cgc aag cat gac ctc ctg atg agg gcg ctg cat tta ttg aag agc ggc 144 Arg Lys His Asp Leu Leu Met Arg Ala Leu His Leu Leu Lys Ser Gly 35 40 45 tgc agc cct gcg gtt cag att aaa atc cga gaa ttg tat aga cgc cga 192 Cys Ser Pro Ala Val Gln Ile Lys Ile Arg Glu Leu Tyr Arg Arg Arg 50 55 60 tat cca cga act ctt gaa gga ctt tct gat tta tcc aca atc aaa tca 240 Tyr Pro Arg Thr Leu Glu Gly Leu Ser Asp Leu Ser Thr Ile Lys Ser 65 70 75 80 tcg gtt ttc agt ttg gat ggt ggc tca tca cct gta gaa cct gac ttg 288 Ser Val Phe Ser Leu Asp Gly Gly Ser Ser Pro Val Glu Pro Asp Leu 85 90 95 gcc gtg gct gga atc cac tcg ttg cct tcc act tca gtt aca cct cac 336 Ala Val Ala Gly Ile His Ser Leu Pro Ser Thr Ser Val Thr Pro His 100 105 110 tca cca tcc tct cct gtt ggt tct gtg ctg ctt caa gat act aag ccc 384 Ser Pro Ser Ser Pro Val Gly Ser Val Leu Leu Gln Asp Thr Lys Pro 115 120 125 aca ttt gag atg cag cag cca tct ccc cca att cct cct gtc cat cct 432 Thr Phe Glu Met Gln Gln Pro Ser Pro Pro Ile Pro Pro Val His Pro 130 135 140 gat gtg cag tta aaa aat ctg ccc ttt tat gat gtc ctt gat gtt ctc 480 Asp Val Gln Leu Lys Asn Leu Pro Phe Tyr Asp Val Leu Asp Val Leu 145 150 155 160 atc aag ccc acg agt tta gtt caa agc agt att cag cga ttt caa gag 528 Ile Lys Pro Thr Ser Leu Val Gln Ser Ser Ile Gln Arg Phe Gln Glu 165 170 175 aag ttt ttt att ttt gct ttg aca cct caa caa gtt aga gag ata tgc 576 Lys Phe Phe Ile Phe Ala Leu Thr Pro Gln Gln Val Arg Glu Ile Cys 180 185 190 ata tcc agg gat ttt ttg cca ggt ggt agg aga gat tat aca gtc caa 624 Ile Ser Arg Asp Phe Leu Pro Gly Gly Arg Arg Asp Tyr Thr Val Gln 195 200 205 gtt cag ttg aga ctt tgc ctg gca gag aca agt tgc cct caa gaa gat 672 Val Gln Leu Arg Leu Cys Leu Ala Glu Thr Ser Cys Pro Gln Glu Asp 210 215 220 aac tat cca aat agt cta tgt ata aaa gta aat ggg aag cta ttt cct 720 Asn Tyr Pro Asn Ser Leu Cys Ile Lys Val Asn Gly Lys Leu Phe Pro 225 230 235 240 ttg cct ggc tat gca cca ccg cct aaa aat ggg att gaa cag aag cgc 768 Leu Pro Gly Tyr Ala Pro Pro Pro Lys Asn Gly Ile Glu Gln Lys Arg 245 250 255 cct gga cgc ccc ttg aat att aca tct tta gtt agg tta tct tca gct 816 Pro Gly Arg Pro Leu Asn Ile Thr Ser Leu Val Arg Leu Ser Ser Ala 260 265 270 gtg cca aac caa att tcc att tct tgg gca tca gaa att ggg aag aat 864 Val Pro Asn Gln Ile Ser Ile Ser Trp Ala Ser Glu Ile Gly Lys Asn 275 280 285 tac tct atg tct gta tat ctt gta cgg cag ctt aca tca gcc atg tta 912 Tyr Ser Met Ser Val Tyr Leu Val Arg Gln Leu Thr Ser Ala Met Leu 290 295 300 tta cag aga tta aaa atg aaa ggt att aga aac cct gat cat tcc aga 960 Leu Gln Arg Leu Lys Met Lys Gly Ile Arg Asn Pro Asp His Ser Arg 305 310 315 320 gca cta att aaa gaa aaa ctt act gca gat cct gat agt gaa att gct 1008 Ala Leu Ile Lys Glu Lys Leu Thr Ala Asp Pro Asp Ser Glu Ile Ala 325 330 335 aca act agc ctt cgg gta tcc ttg atg tgc cct tta gga aaa atg agg 1056 Thr Thr Ser Leu Arg Val Ser Leu Met Cys Pro Leu Gly Lys Met Arg 340 345 350 ctg aca atc cca tgc cgt gca gtg act tgt aca cat ctg cag tgt ttt 1104 Leu Thr Ile Pro Cys Arg Ala Val Thr Cys Thr His Leu Gln Cys Phe 355 360 365 gat gct gcc ctc tat cta caa atg aat gag aaa aag ccc acc tgg att 1152 Asp Ala Ala Leu Tyr Leu Gln Met Asn Glu Lys Lys Pro Thr Trp Ile 370 375 380 tgt cct gtg tgt gac aaa aaa gct gcc tat gaa agt cta ata tta gat 1200 Cys Pro Val Cys Asp Lys Lys Ala Ala Tyr Glu Ser Leu Ile Leu Asp 385 390 395 400 ggg ctt ttt atg gaa att ctc aat gac tgt tct gat gta gat gag atc 1248 Gly Leu Phe Met Glu Ile Leu Asn Asp Cys Ser Asp Val Asp Glu Ile 405 410 415 aaa ttc caa gaa gat ggt tct tgg tgt cca atg aga ccg aag aaa gaa 1296 Lys Phe Gln Glu Asp Gly Ser Trp Cys Pro Met Arg Pro Lys Lys Glu 420 425 430 gct atg aaa gta tcc agc caa ccg tgt aca aaa ata gaa agt tca agc 1344 Ala Met Lys Val Ser Ser Gln Pro Cys Thr Lys Ile Glu Ser Ser Ser 435 440 445 gtc ctc agt aag cct tgt tca gtg act gta gcc agt gag gca agc aag 1392 Val Leu Ser Lys Pro Cys Ser Val Thr Val Ala Ser Glu Ala Ser Lys 450 455 460 aag aaa gta gat gtt att gat ctt aca ata gaa agc tct tct gac gaa 1440 Lys Lys Val Asp Val Ile Asp Leu Thr Ile Glu Ser Ser Ser Asp Glu 465 470 475 480 gag gaa gac cct cct gcc aaa agg aaa tgc atc ttt atg tca gaa aca 1488 Glu Glu Asp Pro Pro Ala Lys Arg Lys Cys Ile Phe Met Ser Glu Thr 485 490 495 caa agc agc cca acc aaa ggg gtt ctc atg tat cag cca tct tct gta 1536 Gln Ser Ser Pro Thr Lys Gly Val Leu Met Tyr Gln Pro Ser Ser Val 500 505 510 agg gtg ccc agt gtg act tcg gtt gat cct gct gct att ccg cct tca 1584 Arg Val Pro Ser Val Thr Ser Val Asp Pro Ala Ala Ile Pro Pro Ser 515 520 525 tta aca gac tac tca gta cca ttc cac cat acg cca ata tca agc atg 1632 Leu Thr Asp Tyr Ser Val Pro Phe His His Thr Pro Ile Ser Ser Met 530 535 540 tca tca gat ttg cca gga gaa caa aga aga aat gat att aat aat gaa 1680 Ser Ser Asp Leu Pro Gly Glu Gln Arg Arg Asn Asp Ile Asn Asn Glu 545 550 555 560 ctg aag ctt gga aca tct tct gat act gtg caa cag tga 1719 Leu Lys Leu Gly Thr Ser Ser Asp Thr Val Gln Gln 565 570 14 572 PRT Homo sapiens 14 Met Ala Asp Phe Glu Glu Leu Arg Asn Met Val Ser Ser Phe Arg Val 1 5 10 15 Ser Glu Leu Gln Val Leu Leu Gly Phe Ala Gly Arg Asn Lys Ser Gly 20 25 30 Arg Lys His Asp Leu Leu Met Arg Ala Leu His Leu Leu Lys Ser Gly 35 40 45 Cys Ser Pro Ala Val Gln Ile Lys Ile Arg Glu Leu Tyr Arg Arg Arg 50 55 60 Tyr Pro Arg Thr Leu Glu Gly Leu Ser Asp Leu Ser Thr Ile Lys Ser 65 70 75 80 Ser Val Phe Ser Leu Asp Gly Gly Ser Ser Pro Val Glu Pro Asp Leu 85 90 95 Ala Val Ala Gly Ile His Ser Leu Pro Ser Thr Ser Val Thr Pro His 100 105 110 Ser Pro Ser Ser Pro Val Gly Ser Val Leu Leu Gln Asp Thr Lys Pro 115 120 125 Thr Phe Glu Met Gln Gln Pro Ser Pro Pro Ile Pro Pro Val His Pro 130 135 140 Asp Val Gln Leu Lys Asn Leu Pro Phe Tyr Asp Val Leu Asp Val Leu 145 150 155 160 Ile Lys Pro Thr Ser Leu Val Gln Ser Ser Ile Gln Arg Phe Gln Glu 165 170 175 Lys Phe Phe Ile Phe Ala Leu Thr Pro Gln Gln Val Arg Glu Ile Cys 180 185 190 Ile Ser Arg Asp Phe Leu Pro Gly Gly Arg Arg Asp Tyr Thr Val Gln 195 200 205 Val Gln Leu Arg Leu Cys Leu Ala Glu Thr Ser Cys Pro Gln Glu Asp 210 215 220 Asn Tyr Pro Asn Ser Leu Cys Ile Lys Val Asn Gly Lys Leu Phe Pro 225 230 235 240 Leu Pro Gly Tyr Ala Pro Pro Pro Lys Asn Gly Ile Glu Gln Lys Arg 245 250 255 Pro Gly Arg Pro Leu Asn Ile Thr Ser Leu Val Arg Leu Ser Ser Ala 260 265 270 Val Pro Asn Gln Ile Ser Ile Ser Trp Ala Ser Glu Ile Gly Lys Asn 275 280 285 Tyr Ser Met Ser Val Tyr Leu Val Arg Gln Leu Thr Ser Ala Met Leu 290 295 300 Leu Gln Arg Leu Lys Met Lys Gly Ile Arg Asn Pro Asp His Ser Arg 305 310 315 320 Ala Leu Ile Lys Glu Lys Leu Thr Ala Asp Pro Asp Ser Glu Ile Ala 325 330 335 Thr Thr Ser Leu Arg Val Ser Leu Met Cys Pro Leu Gly Lys Met Arg 340 345 350 Leu Thr Ile Pro Cys Arg Ala Val Thr Cys Thr His Leu Gln Cys Phe 355 360 365 Asp Ala Ala Leu Tyr Leu Gln Met Asn Glu Lys Lys Pro Thr Trp Ile 370 375 380 Cys Pro Val Cys Asp Lys Lys Ala Ala Tyr Glu Ser Leu Ile Leu Asp 385 390 395 400 Gly Leu Phe Met Glu Ile Leu Asn Asp Cys Ser Asp Val Asp Glu Ile 405 410 415 Lys Phe Gln Glu Asp Gly Ser Trp Cys Pro Met Arg Pro Lys Lys Glu 420 425 430 Ala Met Lys Val Ser Ser Gln Pro Cys Thr Lys Ile Glu Ser Ser Ser 435 440 445 Val Leu Ser Lys Pro Cys Ser Val Thr Val Ala Ser Glu Ala Ser Lys 450 455 460 Lys Lys Val Asp Val Ile Asp Leu Thr Ile Glu Ser Ser Ser Asp Glu 465 470 475 480 Glu Glu Asp Pro Pro Ala Lys Arg Lys Cys Ile Phe Met Ser Glu Thr 485 490 495 Gln Ser Ser Pro Thr Lys Gly Val Leu Met Tyr Gln Pro Ser Ser Val 500 505 510 Arg Val Pro Ser Val Thr Ser Val Asp Pro Ala Ala Ile Pro Pro Ser 515 520 525 Leu Thr Asp Tyr Ser Val Pro Phe His His Thr Pro Ile Ser Ser Met 530 535 540 Ser Ser Asp Leu Pro Gly Glu Gln Arg Arg Asn Asp Ile Asn Asn Glu 545 550 555 560 Leu Lys Leu Gly Thr Ser Ser Asp Thr Val Gln Gln 565 570 15 1866 DNA Homo sapiens CDS (1)..(1866) 15 atg gcg gat ttc gaa gag ttg agg aat atg gtt tct agt ttt agg gtt 48 Met Ala Asp Phe Glu Glu Leu Arg Asn Met Val Ser Ser Phe Arg Val 1 5 10 15 tct gaa cta caa gta tta cta ggc ttt gct gga cgg aat aaa agt gga 96 Ser Glu Leu Gln Val Leu Leu Gly Phe Ala Gly Arg Asn Lys Ser Gly 20 25 30 cgc aag cat gac ctc ctg atg agg gcg ctg cat tta ttg aag agc ggc 144 Arg Lys His Asp Leu Leu Met Arg Ala Leu His Leu Leu Lys Ser Gly 35 40 45 tgc agc cct gcg gtt cag att aaa atc cga gaa ttg tat aga cgc cga 192 Cys Ser Pro Ala Val Gln Ile Lys Ile Arg Glu Leu Tyr Arg Arg Arg 50 55 60 tat cca cga act ctt gaa gga ctt tct gat tta tcc aca atc aaa tca 240 Tyr Pro Arg Thr Leu Glu Gly Leu Ser Asp Leu Ser Thr Ile Lys Ser 65 70 75 80 tcg gtt ttc agt ttg gat ggt ggc tca tca cct gta gaa cct gac ttg 288 Ser Val Phe Ser Leu Asp Gly Gly Ser Ser Pro Val Glu Pro Asp Leu 85 90 95 gcc gtg gct gga atc cac tcg ttg cct tcc act tca gtt aca cct cac 336 Ala Val Ala Gly Ile His Ser Leu Pro Ser Thr Ser Val Thr Pro His 100 105 110 tca cca tcc tct cct gtt ggt tct gtg ctg ctt caa gat act aag ccc 384 Ser Pro Ser Ser Pro Val Gly Ser Val Leu Leu Gln Asp Thr Lys Pro 115 120 125 aca ttt gag atg cag cag cca tct ccc cca att cct cct gtc cat cct 432 Thr Phe Glu Met Gln Gln Pro Ser Pro Pro Ile Pro Pro Val His Pro 130 135 140 gat gtg cag tta aaa aat ctg ccc ttt tat gat gtc ctt gat gtt ctc 480 Asp Val Gln Leu Lys Asn Leu Pro Phe Tyr Asp Val Leu Asp Val Leu 145 150 155 160 atc aag ccc acg agt tta gtt caa agc agt att cag cga ttt caa gag 528 Ile Lys Pro Thr Ser Leu Val Gln Ser Ser Ile Gln Arg Phe Gln Glu 165 170 175 aag ttt ttt att ttt gct ttg aca cct caa caa gtt aga gag ata tgc 576 Lys Phe Phe Ile Phe Ala Leu Thr Pro Gln Gln Val Arg Glu Ile Cys 180 185 190 ata tcc agg gat ttt ttg cca ggt ggt agg aga gat tat aca gtc caa 624 Ile Ser Arg Asp Phe Leu Pro Gly Gly Arg Arg Asp Tyr Thr Val Gln 195 200 205 gtt cag ttg aga ctt tgc ctg gca gag aca agt tgc cct caa gaa gat 672 Val Gln Leu Arg Leu Cys Leu Ala Glu Thr Ser Cys Pro Gln Glu Asp 210 215 220 aac tat cca aat agt cta tgt ata aaa gta aat ggg aag cta ttt cct 720 Asn Tyr Pro Asn Ser Leu Cys Ile Lys Val Asn Gly Lys Leu Phe Pro 225 230 235 240 ttg cct ggc tat gca cca ccg cct aaa aat ggg att gaa cag aag cgc 768 Leu Pro Gly Tyr Ala Pro Pro Pro Lys Asn Gly Ile Glu Gln Lys Arg 245 250 255 cct gga cgc ccc ttg aat att aca tct tta gtt agg tta tct tca gct 816 Pro Gly Arg Pro Leu Asn Ile Thr Ser Leu Val Arg Leu Ser Ser Ala 260 265 270 gtg cca aac caa att tcc att tct tgg gca tca gaa att ggg aag aat 864 Val Pro Asn Gln Ile Ser Ile Ser Trp Ala Ser Glu Ile Gly Lys Asn 275 280 285 tac tct atg tct gta tat ctt gta cgg cag ctt aca tca gcc atg tta 912 Tyr Ser Met Ser Val Tyr Leu Val Arg Gln Leu Thr Ser Ala Met Leu 290 295 300 tta cag aga tta aaa atg aaa ggt att aga aac cct gat cat tcc aga 960 Leu Gln Arg Leu Lys Met Lys Gly Ile Arg Asn Pro Asp His Ser Arg 305 310 315 320 gca cta att aaa gaa aaa ctt act gca gat cct gat agt gaa att gct 1008 Ala Leu Ile Lys Glu Lys Leu Thr Ala Asp Pro Asp Ser Glu Ile Ala 325 330 335 aca act agc ctt cgg gta tcc ttg atg tgc cct tta gga aaa atg agg 1056 Thr Thr Ser Leu Arg Val Ser Leu Met Cys Pro Leu Gly Lys Met Arg 340 345 350 ctg aca atc cca tgc cgt gca gtg act tgt aca cat ctg cag tgt ttt 1104 Leu Thr Ile Pro Cys Arg Ala Val Thr Cys Thr His Leu Gln Cys Phe 355 360 365 gat gct gcc ctc tat cta caa atg aat gag aaa aag ccc acc tgg att 1152 Asp Ala Ala Leu Tyr Leu Gln Met Asn Glu Lys Lys Pro Thr Trp Ile 370 375 380 tgt cct gtg tgt gac aaa aaa gct gcc tat gaa agt cta ata tta gat 1200 Cys Pro Val Cys Asp Lys Lys Ala Ala Tyr Glu Ser Leu Ile Leu Asp 385 390 395 400 ggg ctt ttt atg gaa att ctc aat gac tgt tct gat gta gat gag atc 1248 Gly Leu Phe Met Glu Ile Leu Asn Asp Cys Ser Asp Val Asp Glu Ile 405 410 415 aaa ttc caa gaa gat ggt tct tgg tgt cca atg aga ccg aag aaa gaa 1296 Lys Phe Gln Glu Asp Gly Ser Trp Cys Pro Met Arg Pro Lys Lys Glu 420 425 430 gct atg aaa gta tcc agc caa ccg tgt aca aaa ata gaa agt tca agc 1344 Ala Met Lys Val Ser Ser Gln Pro Cys Thr Lys Ile Glu Ser Ser Ser 435 440 445 gtc ctc agt aag cct tgt tca gtg act gta gcc agt gag gca agc aag 1392 Val Leu Ser Lys Pro Cys Ser Val Thr Val Ala Ser Glu Ala Ser Lys 450 455 460 aag aaa gta gat gtt att gat ctt aca ata gaa agc tct tct gac gaa 1440 Lys Lys Val Asp Val Ile Asp Leu Thr Ile Glu Ser Ser Ser Asp Glu 465 470 475 480 gag gaa gac cct cct gcc aaa agg aaa tgc atc ttt atg tca gaa aca 1488 Glu Glu Asp Pro Pro Ala Lys Arg Lys Cys Ile Phe Met Ser Glu Thr 485 490 495 caa agc agc cca acc aaa ggg gtt ctc atg tat cag cca tct tct gta 1536 Gln Ser Ser Pro Thr Lys Gly Val Leu Met Tyr Gln Pro Ser Ser Val 500 505 510 agg gtg ccc agt gtg act tcg gtt gat cct gct gct att ccg cct tca 1584 Arg Val Pro Ser Val Thr Ser Val Asp Pro Ala Ala Ile Pro Pro Ser 515 520 525 tta aca gac tac tca gta cca ttc cac cat acg cca ata tca agc atg 1632 Leu Thr Asp Tyr Ser Val Pro Phe His His Thr Pro Ile Ser Ser Met 530 535 540 tca tca gat ttg cca ggt ttg gat ttt ctt tcc ctt att cca gtt gat 1680 Ser Ser Asp Leu Pro Gly Leu Asp Phe Leu Ser Leu Ile Pro Val Asp 545 550 555 560 ccc cag tac tgt cct cct atg ttt ttg gat agt ctc acc tca ccc tta 1728 Pro Gln Tyr Cys Pro Pro Met Phe Leu Asp Ser Leu Thr Ser Pro Leu 565 570 575 aca gca agc agt acg tct gtc acc acc acc agc tcc cat gaa agc agt 1776 Thr Ala Ser Ser Thr Ser Val Thr Thr Thr Ser Ser His Glu Ser Ser 580 585 590 act cat gtt agt tca tcc agc agc agg agt gag aca ggg gtc ata acc 1824 Thr His Val Ser Ser Ser Ser Ser Arg Ser Glu Thr Gly Val Ile Thr 595 600 605 agc agt gga agt aac att cct gaa atc atc tca ttg gac taa 1866 Ser Ser Gly Ser Asn Ile Pro Glu Ile Ile Ser Leu Asp 610 615 620 16 621 PRT Homo sapiens 16 Met Ala Asp Phe Glu Glu Leu Arg Asn Met Val Ser Ser Phe Arg Val 1 5 10 15 Ser Glu Leu Gln Val Leu Leu Gly Phe Ala Gly Arg Asn Lys Ser Gly 20 25 30 Arg Lys His Asp Leu Leu Met Arg Ala Leu His Leu Leu Lys Ser Gly 35 40 45 Cys Ser Pro Ala Val Gln Ile Lys Ile Arg Glu Leu Tyr Arg Arg Arg 50 55 60 Tyr Pro Arg Thr Leu Glu Gly Leu Ser Asp Leu Ser Thr Ile Lys Ser 65 70 75 80 Ser Val Phe Ser Leu Asp Gly Gly Ser Ser Pro Val Glu Pro Asp Leu 85 90 95 Ala Val Ala Gly Ile His Ser Leu Pro Ser Thr Ser Val Thr Pro His 100 105 110 Ser Pro Ser Ser Pro Val Gly Ser Val Leu Leu Gln Asp Thr Lys Pro 115 120 125 Thr Phe Glu Met Gln Gln Pro Ser Pro Pro Ile Pro Pro Val His Pro 130 135 140 Asp Val Gln Leu Lys Asn Leu Pro Phe Tyr Asp Val Leu Asp Val Leu 145 150 155 160 Ile Lys Pro Thr Ser Leu Val Gln Ser Ser Ile Gln Arg Phe Gln Glu 165 170 175 Lys Phe Phe Ile Phe Ala Leu Thr Pro Gln Gln Val Arg Glu Ile Cys 180 185 190 Ile Ser Arg Asp Phe Leu Pro Gly Gly Arg Arg Asp Tyr Thr Val Gln 195 200 205 Val Gln Leu Arg Leu Cys Leu Ala Glu Thr Ser Cys Pro Gln Glu Asp 210 215 220 Asn Tyr Pro Asn Ser Leu Cys Ile Lys Val Asn Gly Lys Leu Phe Pro 225 230 235 240 Leu Pro Gly Tyr Ala Pro Pro Pro Lys Asn Gly Ile Glu Gln Lys Arg 245 250 255 Pro Gly Arg Pro Leu Asn Ile Thr Ser Leu Val Arg Leu Ser Ser Ala 260 265 270 Val Pro Asn Gln Ile Ser Ile Ser Trp Ala Ser Glu Ile Gly Lys Asn 275 280 285 Tyr Ser Met Ser Val Tyr Leu Val Arg Gln Leu Thr Ser Ala Met Leu 290 295 300 Leu Gln Arg Leu Lys Met Lys Gly Ile Arg Asn Pro Asp His Ser Arg 305 310 315 320 Ala Leu Ile Lys Glu Lys Leu Thr Ala Asp Pro Asp Ser Glu Ile Ala 325 330 335 Thr Thr Ser Leu Arg Val Ser Leu Met Cys Pro Leu Gly Lys Met Arg 340 345 350 Leu Thr Ile Pro Cys Arg Ala Val Thr Cys Thr His Leu Gln Cys Phe 355 360 365 Asp Ala Ala Leu Tyr Leu Gln Met Asn Glu Lys Lys Pro Thr Trp Ile 370 375 380 Cys Pro Val Cys Asp Lys Lys Ala Ala Tyr Glu Ser Leu Ile Leu Asp 385 390 395 400 Gly Leu Phe Met Glu Ile Leu Asn Asp Cys Ser Asp Val Asp Glu Ile 405 410 415 Lys Phe Gln Glu Asp Gly Ser Trp Cys Pro Met Arg Pro Lys Lys Glu 420 425 430 Ala Met Lys Val Ser Ser Gln Pro Cys Thr Lys Ile Glu Ser Ser Ser 435 440 445 Val Leu Ser Lys Pro Cys Ser Val Thr Val Ala Ser Glu Ala Ser Lys 450 455 460 Lys Lys Val Asp Val Ile Asp Leu Thr Ile Glu Ser Ser Ser Asp Glu 465 470 475 480 Glu Glu Asp Pro Pro Ala Lys Arg Lys Cys Ile Phe Met Ser Glu Thr 485 490 495 Gln Ser Ser Pro Thr Lys Gly Val Leu Met Tyr Gln Pro Ser Ser Val 500 505 510 Arg Val Pro Ser Val Thr Ser Val Asp Pro Ala Ala Ile Pro Pro Ser 515 520 525 Leu Thr Asp Tyr Ser Val Pro Phe His His Thr Pro Ile Ser Ser Met 530 535 540 Ser Ser Asp Leu Pro Gly Leu Asp Phe Leu Ser Leu Ile Pro Val Asp 545 550 555 560 Pro Gln Tyr Cys Pro Pro Met Phe Leu Asp Ser Leu Thr Ser Pro Leu 565 570 575 Thr Ala Ser Ser Thr Ser Val Thr Thr Thr Ser Ser His Glu Ser Ser 580 585 590 Thr His Val Ser Ser Ser Ser Ser Arg Ser Glu Thr Gly Val Ile Thr 595 600 605 Ser Ser Gly Ser Asn Ile Pro Glu Ile Ile Ser Leu Asp 610 615 620 17 2105 DNA Homo sapiens CDS (94)..(1458) 17 gttgccatta ggggactcct gaggtcctat ctccaggctg cggtgactgc actttccctg 60 gagtggaagc tgctggaagg cggaccggcc gcc atg tcc acg ttc agg cag gag 114 Met Ser Thr Phe Arg Gln Glu 1 5 gac gtg gag gac cat tat gag atg ggg gag gag ctg ggc agc ggc cag 162 Asp Val Glu Asp His Tyr Glu Met Gly Glu Glu Leu Gly Ser Gly Gln 10 15 20 ttt gcg atc gtg cgg aag tgc cgg cag aag ggc acg ggc aag gag tac 210 Phe Ala Ile Val Arg Lys Cys Arg Gln Lys Gly Thr Gly Lys Glu Tyr 25 30 35 gca gcc aag ttc atc aag aag cgc cgc ctg tca tcc agc cgg cgt ggg 258 Ala Ala Lys Phe Ile Lys Lys Arg Arg Leu Ser Ser Ser Arg Arg Gly 40 45 50 55 gtg agc cgg gag gag atc gag cgg gag gtg aac atc ctg cgg gag atc 306 Val Ser Arg Glu Glu Ile Glu Arg Glu Val Asn Ile Leu Arg Glu Ile 60 65 70 cgg cac ccc aac atc atc acc ctg cac gac atc ttc gag aac aag acg 354 Arg His Pro Asn Ile Ile Thr Leu His Asp Ile Phe Glu Asn Lys Thr 75 80 85 gac gtg gtc ctc atc ctg gag ctg gtc tct ggc ggg gag ctc ttt gac 402 Asp Val Val Leu Ile Leu Glu Leu Val Ser Gly Gly Glu Leu Phe Asp 90 95 100 ttc ctg gcg gag aaa gag tcg ctg acg gag gac gag gcc acc cag ttc 450 Phe Leu Ala Glu Lys Glu Ser Leu Thr Glu Asp Glu Ala Thr Gln Phe 105 110 115 ctc aag cag atc ctg gac ggc gtt cac tac ctg cac tct aag cgc atc 498 Leu Lys Gln Ile Leu Asp Gly Val His Tyr Leu His Ser Lys Arg Ile 120 125 130 135 gca cac ttt gac ctg aag ccg gaa aac atc atg ctg ctg gac aag aac 546 Ala His Phe Asp Leu Lys Pro Glu Asn Ile Met Leu Leu Asp Lys Asn 140 145 150 gtg ccc aac cca cga atc aag ctc atc gac ttc ggc atc gcg cac aag 594 Val Pro Asn Pro Arg Ile Lys Leu Ile Asp Phe Gly Ile Ala His Lys 155 160 165 atc gag gcg ggg aac gag ttc aag aac atc ttc ggc acc ccg gag ttt 642 Ile Glu Ala Gly Asn Glu Phe Lys Asn Ile Phe Gly Thr Pro Glu Phe 170 175 180 gtg gcc cca gag att gtg aac tat gag ccg ctg ggc ctg gag gcg gac 690 Val Ala Pro Glu Ile Val Asn Tyr Glu Pro Leu Gly Leu Glu Ala Asp 185 190 195 atg tgg agc atc ggt gtc atc acc tat atc ctc ctg agc ggt gca tcc 738 Met Trp Ser Ile Gly Val Ile Thr Tyr Ile Leu Leu Ser Gly Ala Ser 200 205 210 215 ccg ttc ctg ggc gag acc aag cag gag acg ctc acc aac atc tca gcc 786 Pro Phe Leu Gly Glu Thr Lys Gln Glu Thr Leu Thr Asn Ile Ser Ala 220 225 230 gtg aac tac gac ttc gac gag gag tac ttc agc aac acc agc gag ctg 834 Val Asn Tyr Asp Phe Asp Glu Glu Tyr Phe Ser Asn Thr Ser Glu Leu 235 240 245 gcc aag gac ttc att cgc cgg ctg ctc gtc aaa gat ccc aag cgg aga 882 Ala Lys Asp Phe Ile Arg Arg Leu Leu Val Lys Asp Pro Lys Arg Arg 250 255 260 atg acc att gcc cag agc ctg gaa cat tcc tgg att aag gcg atc cgg 930 Met Thr Ile Ala Gln Ser Leu Glu His Ser Trp Ile Lys Ala Ile Arg 265 270 275 cgg cgg aac gtg cgt ggt gag gac agc ggc cgc aag ccc gag cgg cgg 978 Arg Arg Asn Val Arg Gly Glu Asp Ser Gly Arg Lys Pro Glu Arg Arg 280 285 290 295 cgc ctg aag acc acg cgt ctg aag gag tac acc atc aag tcg cac tcc 1026 Arg Leu Lys Thr Thr Arg Leu Lys Glu Tyr Thr Ile Lys Ser His Ser 300 305 310 agc ttg ccg ccc aac aac agc tac gcc gac ttc gag cgc ttc tcc aag 1074 Ser Leu Pro Pro Asn Asn Ser Tyr Ala Asp Phe Glu Arg Phe Ser Lys 315 320 325 gtg ctg gag gag gcg gcg gcc gcc gag gag ggc ctg cgc gag ctg cag 1122 Val Leu Glu Glu Ala Ala Ala Ala Glu Glu Gly Leu Arg Glu Leu Gln 330 335 340 cgc agc cgg cgg ctc tgc cac gag gac gtg gag gcg ctg gcc gcc atc 1170 Arg Ser Arg Arg Leu Cys His Glu Asp Val Glu Ala Leu Ala Ala Ile 345 350 355 tac gag gag aag gag gcc tgg tac cgc gag gag agc gac agc ctg ggc 1218 Tyr Glu Glu Lys Glu Ala Trp Tyr Arg Glu Glu Ser Asp Ser Leu Gly 360 365 370 375 cag gac ctg cgg agg cta cgg cag gag ctg ctc aag acc gag gcg ctc 1266 Gln Asp Leu Arg Arg Leu Arg Gln Glu Leu Leu Lys Thr Glu Ala Leu 380 385 390 aag cgg cag gcg cag gag gag gcc aag ggc gcg ctg ctg ggg acc agc 1314 Lys Arg Gln Ala Gln Glu Glu Ala Lys Gly Ala Leu Leu Gly Thr Ser 395 400 405 ggc ctc aag cgc cgc ttc agc cgc ctg gag aac cgc tac gag gcg ctg 1362 Gly Leu Lys Arg Arg Phe Ser Arg Leu Glu Asn Arg Tyr Glu Ala Leu 410 415 420 gcc aag caa gta gcc tcc gag atg cgc ttc gtg cag gac ctc gtg cgc 1410 Ala Lys Gln Val Ala Ser Glu Met Arg Phe Val Gln Asp Leu Val Arg 425 430 435 gcc ctg gag cag gag aag ctg cag ggc gtg gag tgc ggg ctg cgc tag 1458 Ala Leu Glu Gln Glu Lys Leu Gln Gly Val Glu Cys Gly Leu Arg 440 445 450 gcgcagtggg gtgggccagg ccccaggaca gccggagctc ggcctgcggt gggggcgctt 1518 cctgtggacg ctgcgcctcc catcgcccgg gtgcctgtcc ttgcccagcg ccaccaggct 1578 ggaggcggag tgggaggagc tggagccagg cccgtaagtt cgcaggcagg ggtgggtgtg 1638 ggacggggct gcttctctac acagcctcta cgctggcctt caccttcacc cctgcatcgt 1698 cggtgaccct gggaccctcc aggcagcgtg gcctgtggca ccgtgagggt tgggacccac 1758 cgaggcgcag aggcggcccg aatgcagccc tggttcaggc ccggaggagg gtttgcgggt 1818 agttgcacgg acaattcggc ggggtgctgc ctgttgctgc cattagccca ggaggaggtc 1878 gtgggacggg gagggtggga tggacggcgg acaggcagtc cccacgctgc tgggtggcgc 1938 cgggcttggt ggggtcttcc actgtgtgcc cttctcgccg aggccggtcc cccgggtgtg 1998 gggtgccctg ctgcggactc ctccgcgagc cccatcgtcg cgcctgtgga cgcctaggca 2058 agagcggccc tctgcagcca agagaaataa aatactggct tccagat 2105 18 454 PRT Homo sapiens 18 Met Ser Thr Phe Arg Gln Glu Asp Val Glu Asp His Tyr Glu Met Gly 1 5 10 15 Glu Glu Leu Gly Ser Gly Gln Phe Ala Ile Val Arg Lys Cys Arg Gln 20 25 30 Lys Gly Thr Gly Lys Glu Tyr Ala Ala Lys Phe Ile Lys Lys Arg Arg 35 40 45 Leu Ser Ser Ser Arg Arg Gly Val Ser Arg Glu Glu Ile Glu Arg Glu 50 55 60 Val Asn Ile Leu Arg Glu Ile Arg His Pro Asn Ile Ile Thr Leu His 65 70 75 80 Asp Ile Phe Glu Asn Lys Thr Asp Val Val Leu Ile Leu Glu Leu Val 85 90 95 Ser Gly Gly Glu Leu Phe Asp Phe Leu Ala Glu Lys Glu Ser Leu Thr 100 105 110 Glu Asp Glu Ala Thr Gln Phe Leu Lys Gln Ile Leu Asp Gly Val His 115 120 125 Tyr Leu His Ser Lys Arg Ile Ala His Phe Asp Leu Lys Pro Glu Asn 130 135 140 Ile Met Leu Leu Asp Lys Asn Val Pro Asn Pro Arg Ile Lys Leu Ile 145 150 155 160 Asp Phe Gly Ile Ala His Lys Ile Glu Ala Gly Asn Glu Phe Lys Asn 165 170 175 Ile Phe Gly Thr Pro Glu Phe Val Ala Pro Glu Ile Val Asn Tyr Glu 180 185 190 Pro Leu Gly Leu Glu Ala Asp Met Trp Ser Ile Gly Val Ile Thr Tyr 195 200 205 Ile Leu Leu Ser Gly Ala Ser Pro Phe Leu Gly Glu Thr Lys Gln Glu 210 215 220 Thr Leu Thr Asn Ile Ser Ala Val Asn Tyr Asp Phe Asp Glu Glu Tyr 225 230 235 240 Phe Ser Asn Thr Ser Glu Leu Ala Lys Asp Phe Ile Arg Arg Leu Leu 245 250 255 Val Lys Asp Pro Lys Arg Arg Met Thr Ile Ala Gln Ser Leu Glu His 260 265 270 Ser Trp Ile Lys Ala Ile Arg Arg Arg Asn Val Arg Gly Glu Asp Ser 275 280 285 Gly Arg Lys Pro Glu Arg Arg Arg Leu Lys Thr Thr Arg Leu Lys Glu 290 295 300 Tyr Thr Ile Lys Ser His Ser Ser Leu Pro Pro Asn Asn Ser Tyr Ala 305 310 315 320 Asp Phe Glu Arg Phe Ser Lys Val Leu Glu Glu Ala Ala Ala Ala Glu 325 330 335 Glu Gly Leu Arg Glu Leu Gln Arg Ser Arg Arg Leu Cys His Glu Asp 340 345 350 Val Glu Ala Leu Ala Ala Ile Tyr Glu Glu Lys Glu Ala Trp Tyr Arg 355 360 365 Glu Glu Ser Asp Ser Leu Gly Gln Asp Leu Arg Arg Leu Arg Gln Glu 370 375 380 Leu Leu Lys Thr Glu Ala Leu Lys Arg Gln Ala Gln Glu Glu Ala Lys 385 390 395 400 Gly Ala Leu Leu Gly Thr Ser Gly Leu Lys Arg Arg Phe Ser Arg Leu 405 410 415 Glu Asn Arg Tyr Glu Ala Leu Ala Lys Gln Val Ala Ser Glu Met Arg 420 425 430 Phe Val Gln Asp Leu Val Arg Ala Leu Glu Gln Glu Lys Leu Gln Gly 435 440 445 Val Glu Cys Gly Leu Arg 450 19 66 DNA Artificial Sequence synthetic DNA 19 tctagtcgac ggccagtgaa ttgtaatacg actcactata gggcgttttt tttttttttt 60 tttttt 66 20 21 DNA Artificial Sequence synthetic DNA 20 ctgcggtatg gcaactttca g 21 21 20 DNA Artificial Sequence synthetic DNA 21 aggaatgcca agacatgcaa 20 22 24 DNA Artificial Sequence synthetic DNA 22 aactacggca agagctactc ggtg 24 23 24 DNA Artificial Sequence synthetic DNA 23 gttcatctgc aggtagaaga cggc 24 

1. A method for detecting chronic myeloid leukemia comprising the step of measuring expression level of a gene selected from the group consisting of IFIT-2 gene, LAGE-I gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene in a test tissue or a test cell; or determining expression profile of a gene group containing at least one of said genes so as to thereby detect chronic myeloid leukemia.
 2. A method for detecting chronic myeloid leukemia according to claim 1 wherein the test cell is a bone marrow cell or a blood cell.
 3. A method for detecting chronic myeloid leukemia according to claim 2 wherein the bone marrow cell or the blood cell is pluripotent hematopoietic stem cell.
 4. A method for detecting chronic myeloid leukemia according to claim 3 wherein the pluripotent hematopoietic stem cell is a AC 133 protein-positive cell.
 5. A method for detecting chronic myeloid leukemia according to claim 1 wherein the measurement of the gene expression level or the determination of the expression profile of the gene group is carried out at the level of mRNA.
 6. A method for detecting chronic myeloid leukemia according to claim 5 wherein the measurement of the gene expression level or the determination of the expression profile of the gene group at the level of mRNA is carried out by means of gene amplification and/or by using a DNA microarray.
 7. A method for detecting chronic myeloid leukemia according to claim 1 wherein the measurement of the gene expression level or the determination of the expression profile of the gene group is carried out at the level of protein.
 8. A method for detecting chronic myeloid leukemia according to claim 7 wherein the measurement of the gene expression level or the determination of the expression profile of the gene group at the level of protein is carried out by means of immunological method and/or by using a protein chip.
 9. A method for determining phase of chronic myeloid leukemia wherein the phase of the chronic myeloid leukemia is determined by using the detection method of chronic myeloid leukemia according to any one of claims 1 to
 8. 10. A method for determining phase of chronic myeloid leukemia according to claim 9 wherein the phase of the chronic myeloid leukemia is selected from the group consisting of chronic phase, accelerated phase, and blastic phase.
 11. A method for evaluating a compound for its effectiveness in treating or preventing chronic myeloid leukemia, comprising the steps of: (a) administering the compound to be evaluated to a test animal or a test cell, or bringing the compound in contact with a test animal or a test cell; and (b) confirming whether the compound regulates expression level of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene, or a gene which is functionally equivalent to such gene in test animal or the test cell.
 12. A method for evaluating a compound for its effectiveness in treating or preventing chronic myeloid leukemia, comprising the steps of: (a) bringing the compound to be evaluated in contact with a test animal or a test cell containing a fusion gene of an expression-regulatory region for a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene; and a reporter gene; and (b) measuring the level of the reporter gene expressed in the test animal or the test cell to evaluate the compound.
 13. A method for evaluating a compound for its effectiveness in treating or preventing chronic myeloid leukemia, comprising the steps of: (a) bringing the compound to be evaluated in contact with a protein encoded by a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene; and (b) measuring the activity of the protein to evaluate the compound.
 14. A method for evaluating a compound for its effectiveness in treating or preventing chronic myeloid leukemia, comprising the steps of: (a) bringing the compound to be evaluated in contact with a STAT protein whose activity is inhibited by a protein encoded by PIASy gene, PIASx-α gene, or PIASx-β gene; and (b) measuring the activity of the STAT protein to evaluate the compound.
 15. A therapeutic or prophylactic agent for chronic myeloid leukemia comprising a compound obtained by the evaluation method of any one of claims 11 to 14 as an active ingredient.
 16. A reagent for research purpose, or an agent for detection, treatment, or prevention of chronic myeloid leukemia comprising an antibody directed against a protein encoded by a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene.
 17. A method for evaluating the risk of being susceptible for chronic myeloid leukemia comprising the step of detecting a genetic polymorphism which causes abnormality in expression level of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3.
 18. A method for evaluating the risk of being susceptible to chronic myeloid leukemia comprising the step of detecting a genetic polymorphism which causes abnormality in biological activity of the protein encoded by a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene, and DAPK3 gene.
 19. A therapeutic or prophylactic agent for chronic myeloid leukemia comprising an antisense nucleic acid which is capable of specifically hybridizing with mRNA of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, and ETS2 gene.
 20. A therapeutic or prophylactic agent for chronic myeloid leukemia comprising a ribozyme capable of specifically cleaving mRNA of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, and ETS2 gene. 